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ABSTRACT
As the Nigerian economy continues to grow, more multinational pharmaceutical companies are being attracted to this
market.

However, new companies as well as those presently

operating in Nigeria, are faced with a fundamental problem
typical for companies doing business in developing countries.
This problem is lack of information important in decision
making.
There is a general lack of information and understanding
of Nigeria's pharmaceutical legislations.

Consequently,

companies are forced to make many important decisions on the
basis of lack of, or at best, incomplete information.

In

addition, little is presently known about industrial pharmaceutical practices in Nigeria.
This study sought to aleviate the problem by presenting
selected portions of Nigeria's pharmaceutical legislations
and comparing them to United States drug laws.

The two systems

were described and explained.
The methodology consisted of two parts.

First, the study

analyzed major sections of Nigeria's pharmaceutical laws and
compared them to United States drug legislations.
differences were identified and

Major

explained.

The second part of the study consisted of gathering
primary data from major United States and European pharmaceutical companies doing business in Nigeria .

iii

Responses

obtained were compared to facts secured from the literature
search.
Although the research was exploratory in nature rather
than conclusive, the following conditions appear to exist:
1.

There is a general lack of understanding of the
Nigerian Food and Drug laws.

2.

The laws themselves appear to be confusing with
numerous loopholes.

J.

The Nigerian legal environment is less stringent
than ih the United States.

4.

Specifically, drug introduction legislation was
found to be much less stringent in 'Nigeria than
in the United States.

5.

Drug Registration is not of major concern to
pharmaceutical companies in Nigeria.

iv
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I.

INTRODUCTION

Statement of the Problem
All areas of the pharmaceutical industry are constantly
reminded of the controls imposed by government.

It is even

more so in the United States where there are relatively
more accommodating conditions such as those existing in
developing nations of the world, particularly Nigeria.

As

manufacturers move their technology to these areas, they
face greater challenges for which they are unprepared, and
they are forced to make changes in their policies and strategies as conditions dictate.
There is an abundance of research information on the
United States pharmaceutical industry.

For example, much

research has been done in areas of manufacturing, distribution
and promotion.

In addition, these functions have frequently

been studies in relation to prevailing legal environments
at the time.

Unfortunately, there has been a great lack

of research data on the developing areas of the world.

For

example, this student examined the research library of one
of the largest pharmaceutical companies in the world in
early 1976, and found very little information on developing
countries.

The Marketing Research Division of the company

admitted that this was the most difficult problem faced by
its company in its operation in Nigeria.

Because of Nigeria's

2.

status as a "third world country," researchers have ignored
its pharmaceutical problems.

Therefore, managers have been

forced to depend heavily on their intuition in making
important marketing decisions in Nigeria and developing
countries.
Moreover, it is difficult to make decisions about
Nigerian problems based on experience in other countries
because of its uniqueness .
position in Africa.

It is unique because of its

It is perhaps the richest and certainly

the most populous country in Africa; and it is the single
largest potential market on that continent.

For these

reasons, it has attracted the attention of international
marketers.

As it becomes increasingly important for pharma-

ceutical companies to understand fully all aspects of the
environment within which they must operate.
Since these pharmaceutical companies have to operate
within the provisions of Nigerian laws, research into the
legal environment surrounding Nigeria's pharmaceutical
industry will help fill the vacuum currently existing.
By g iving a description of the Nigerian market and the
laws that guide it and relating this in terms of the American
pharmaceutical laws, manufacturers and marketers will be
better equiped to make good operational decisions and also
avoid undue risks.
On looking critically at various Nigerian laws, it can
be seen that the basic tie between the United States as a
former British colony and Nigeria as a more recent independent

3.
nation of the British Empire, exists.
in the areas of pharmaceutical laws.

It is even more obvious
On the other hand there

is a distinction between the t wo systems which is unique
to each country.

This study is designed to identify the

similarities between United States and Nig erian drug laws
and to help explain the differences between the t wo systems.
In addition, the study will explore the influence these
differing legal systems may have on the multinational pharmaceutical marketer,
Justification
On beginning this study, it was felt that it would be
difficult to compare the drug laws of the two systems mainly
because of apparent differences in social and cultural
histories and more obvious differences in level of technolog~cal

and scientific development.

However, both countries have a lot

~n

common.

For

example, both countries are former colonies of the United
Kingdom and both have operated under the provisions of the
British Common Laws at the initial parts of their respective
histories.

Indeed, the laws of both countries today are

based on the premise of the British Law.

Both countries,

particularly the United States, have built or are building
8

strong free enterprise system which encourages free compe-

tition.
Nigeria since independence in 1960, and particularly
over the last two years has been forg ing a system closely
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resembling that of the United States; in education, government, ac ience and technology.
over the last few years, the trade between these two
countries, each a giant in her own geographical region, is
enormous and rising.

In Nigeria, just as in the United States,

much more money and effort are being devoted to wiping out
poverty and disease than ever before.

Massive education

programs have been begun towards this goal, particularly
as demonstrated in the Third National Development Plan (19751980).

More emphasis will be placed on preventive medical

care and environmental health.
It is anticipated that more laws will emerge as Nigerians
become mor e sophisticated in their health demands.

Since the

pharmaceut i cal industry has to operate within the boundaries
of these laws , it is essential that this study be undertaken
i n order to identify potential problem areas.
Objectives of the Study
1.

The study is aimed at finding the similarities and

the difference s between the pharmaceutical laws of both
countries unde r consideration.
2.

To f ocus the attention of the international phar-

maceutical companies on the growing importance of Nigeria as
a market f or pharmaceuticals in Africa.

J.

To point out the inadequacies in the drug laws of

Ni geria.

4.

To identify the needs of the people in areas of

health manpower and health facilities.

5.
5.

To try to relate the laws enacted in Nigeria to

the prevailing conditions at the time of enactment.

6.

To compare the impact of pharmaceutical laws in

both countries particularly as they affect the multinational
companies in their operations in Nigeria.

7.

To attempt to confirm what has been empirically

known for a whiles

that drug introduction legislation

in Nigeria is much easier than in the United States.
8.

To explore the influence the differing legal systems

may have on the multinational pharmaceutical marketer.
Methodology
The methodology used for this project involved two facets.
The first activity consisted of an extensive literature
search into the major relevant areas of the pharmaceutical
laws of both countries.
This was done by obtaining several relevant publications
from the Embassy of Nigeria in Washington, Nigerian Consulate
General in New York, the U.S. Department of State and the
U.S. Department of Commerce.

Other relevant data were obtained

through written communication with physicians, pharmacists,
college professors, and pharmaceutical marketing executives,
particularly Pfizer Inc. in New York City.

Further important

materials were obtained from the U.S. Department of Health,
Education and Welfare in Washington.
Using the University library and the Department of
Pharmacy Administration library as major sources of information,
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many other books and journals, articles and several publications were used as sources of comparison between the t wo
systems under consideration.

Major differences were identified.

It sho uld be noted that no such research of this nature
has ever been done and the data obtained, particularly those
from Ni geria consist of very many incomplete information
on which empirical decisions have been made.

This has made

it necessary to design the methodology in two parts in order
to substant iate many of the things that have been identified
in the firs t part.
The s ec ond activity consisted of gathering primary data
from a sample of pharmaceutical companies.

Respondents were

the execut i ves of the international divisions of major
pharmaceutic al companies in the United States.

In Nigeria,

General Mana gers, Managing Directors and Directors of
thirteen drug companies were selected.
Cons i de ring the geographical locations of the executives,
the resourc es available to the student, in terms of cost and
time and t he ready availability of a good mailing list for
potential participants, it was deemed prudent to conduct
the invest iga tion by mail questionnaire.
Fifty-two addresses were extracted from the National
Wholesale Druggists Association publication - 1976 Membership
and Executive Directory.

The officers addressed in the

United State s were Vice Presidents, Presidents and Directors
of the I nte rnational Divisions of the drug companies.

The
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thirteen addresses in Nigeria were obtained from the U.S.
Department of State publication of the directory of foreign
pharmaceutical companies in Nigeria.

All thirteen companies

have headquarters in either the United States or in European
countries.

Altogether, a total of sixty-five companies

were obtained in both countries.
The quesionnaire was developed and a pretest was conducted
among a carefully selected group of pharmaceutical companies
in northeastern United States.
The questionnaire was revised and mailed to the sample
of companies selected for the survey.

Many of the executives

wrote back immediately: some refusing to participate in the
study as a matter of corporate policy, others indicated that
responding to the questions would betray vital trade secrets.
Several calls were made to companies and reminder letters
(see appendix) were mailed to them asking for .responses.

At

this time three more companies returned the questionnaires.
Further efforts resulted in a return of only one more questionnaire from Nigeria--the only response received from the
thirteen mailed to Nigeria,
Altogether, a total of t wenty companies responded, only
six of which filled out the questionnaire as desired--a
response rate of approximately nine percent.
The analysis of the responses is utilized as a finale
to the investigation.

It has been introduced at this point

in order to prepare the reader for the format and design of

8.
the inves t igation.

The analysis is presented in Chapter VI.

Layout of the Project
This study consists of seven chapters.

The following

chapter provides a background information about Nigeria
from the co lonial days through independence in 1960 to the
present.
Chapter III provides a profile of the health care industry
and leads on to chapter IV which deals with the evolution
of the pharmaceutical laws of the two countries under consideration .
The fifth chapter provides a discussion comparing selected
areas of the Nigerian and United States pharmaceutical laws.
Chapter VI describes the attitudes of the pharmaceutical
companies a s found in the survey, and chapter VII summarizes
the study's c onclusion and provides suggestions for further
research.

II.

GENERAL INFORNATION ABOUT NIGERIA

Geography
Nigeria, located on the West Coast of Africa, is
bounded on the south by the Gulf of Guinea, on the north by
the country of Niger and Chad Republic ; on the east by the
Cameroon and on the west by the Peoples Republic of Benin,
formerly known as Dahomey.
It covers an area of 357,000 square miles, which makes
it about the size of California, Nevada and Arizona combined.
Thus it is the largest nation on the west of coast of Africa,
and with a population of nearly 80 million, it is the most
populous country on the continent of Africa .

It is estimated

that one out of every five Africans , south of the Sahara, is
a Nigerian.
Topography
Four main topographical areas may be distinguished in
terms of ve getat ion and climate s
1.

The hot, humid coastal belt of Mangrove Swamp,

10-16 miles wide,
2.

The tropical Rain Forest and oil palm bush, 50-100

miles wide north-bo und ,

J.

The re l a tively dry central plateau of open woodland

and savanah, covering
·
th e grea t er part of t h e nort h ern region
·
and

10 .
4.

The semi - desert, bordering the neighboring country

of Niger in the extreme north.
Climate
Nigeria' s t wo main seasons--the dry season and the wet
season, can be further classified into four types of seasons,
making it comparable to the winter , spring , summer and fall
seasons of North America.

The winter can be compared to

Nigeria's hamattan season between the months of November and
February.

At this time it is dry , dusty and cold.

In

contrast to the American winter , it never snows in Nigeria
and the coldest i t ever gets is perhaps as cold as a
beautiful spring morning in the United States .
The three months following the dry season , February,
March and April , may be analogous to the American spring
season.

It is nic e and beautiful.

rather cool at n ight .

It is warm in the day and

Temperatures range between 65° and 70°

in the south but down in the 50 ' s in the extreme northern
part of Nigeria.
The wet season begins earlier in the south in the month
of May and overlaps into the dry season much as spring overlaps into early summer in North America .

Rainfall varies

from 20 inches per a nnum in the north to as much as 150 inches
Per annum in the so uth . The rains taper off around September
and yields
·
to the more pleasant fall-like weather when leaves
turn brown and wither and grounds become dry and dusty once
again.

11.
People of Nigeria
Nigeria forms a conglomerate of heterogeneous tribal
groups ever present in any country in Africa.

Over 150 tribal

groups are represented, with languages that differ from one
another much as English differs from French.
This heterogeneity has brought about serious anxiety and
fear of domination among Nigeria's minority groups and has
been one of Nigeria's main obstacles to forming a strong and
united nation.

Indeed, it has resulted in one of the most

bitter civil wars ever fought on the continent of Africa.
History of Nigeria
The area now known as Nigeria has had a long and eventful history even before the colonial period.

The northern

cities of Kano, Kaduna and Sokoto have had a recorded history
dating back to 1100 AD.

Along with the Bornu Empire in the

north east corner, the Hausa Kingdoms in the north have served
as the important link between the Islamic haven of Mecca in
modern Saudi Arabia and the Yoruba Kingdom of Oya, in southern
Nigeria.
During the 17th and 18 centuries, the effect of the slave
trade and the inter-tribal wars was a disintegration of
political edifice of these Kingdoms, particularly those of
the Oyo Kingdom and the ancient Empire of Benin.

The Hausa

Emirate of Northern Nigeria was further disintegrated by the
Fulani crusader--Usman Dan Fodio, who established the Islamic
faith of which about 47 percent of the present Nigerian
Population belongs.

12.
The arrival of Europeans in Benin in the 15th and 16th
centuries signalled the beginning of the colonization of
Nigeria.

In 1885, the British had been widely recognized

as an influential power and colonial owner of this part of
Africa.

In 1900, this territory came under the direct con-

trol of the British government.
In 1914, the 100,000 square miles which was Usman Dan
Fodio's territory was united with the southern provinces
inlcuding Lagos Colony and called the "Colony and Protectorate of Nigeria."
From 1922 to 1943 , Nigerian nationals were incorporated
into the government as legislators and executives under the
jurisdiction of the British Governor's Cabinet.

During this

period, successive constitutions legislated by the British
government formulated a.federal government structure (with
powerful federal executive and less so powerful state governments) which has persisted until today.
Events in Nigeria since Independence in 1960
October 1, 1960, marked the turning point in the history
of Nigeria when it was granted full independence as a
Federation of three disproportionate divisions of Northern
Region (over 100,000 square miles in area and more than 50
Percent of the population of Nigeria) ; and both the Eastern
and Western Regions of Nigeria which when taken together,
constitute less than 50 percent of Nigeria.

13.
Admin istration of the country was handed over to the
Northern bor n Abubakar Tafawa Balewa who became the Prime
Minister.

I n 1963 , Nigeria broke its last ties with the

United Kingdom when it became a Republic.
Tribal an d regional tensions moun ted as politicians became
corrupt and unresponsive to the wishes of the people.

Fear

of Ibo domination transformed into fear of Hausa domination
and Nigeria plunged deeper and deeper into fear chaos and
political ann i hilation .

Power struggle mounted at the Federa;

level as the Ibo t ried to participate in the Federal structure
and the Hausa r efused to share its political power.

The

leaderless Yorubas* looked on as the strife plummeted into
a bitter and vicious struggle among the politicians .
The c l imax was reached on January 15, 1966, when a
dissident section of the Nigerian Army overthrew the Civilian
government of Balewa in a coup-de-tat and brought an Ibo-born
Major-General J . T.U . Aguiyi Ironsi to power.

Ironsi abolished

the Federal s t r ucture and inaugurated in its place a Unitary
form of gove r nment which in essence put the leadership of the
country in the hands of an elite few and threw the country
further i nto uncertainty and fear as thousands of Ibos were
murdered in protest in Northern Nigeria.
;obafemi Awol owo, the respected Yoruba leader was jailed
or ten years on charges of treason.

14.
A counter coup which catapulted a Tiv-born Lt. Col.
Yakubu Gowen to power was implemented on July 29, 1966.
Ironsi was killed .
Lt. Col . Odumegwu Ojukwu, the Military Governore of
Eastern Nige ria, himself an Ibo, saw this as a means of perpetuating a Northern Dynasy of rulers and refused to give
his allegi anc e to the Gowan regime.

On May 27, 1967, Gowon

promulgate d a decree creating twelve states out of the four
main regions .

Ojukwu responded by proclaiming an Independent

state of Biafra from the Eastern Region.

War broke out on

July 6, 1967 , and lasted for two and a half years.
After nine years of rule, Gowon's regime was toppled
in a b l oo dle s s coup by yet another northern-born Brigadier
Murtala Mohammed.

Mohammed was killed in an unsuccessful

coup attemp t on February 13, 1976, and was succeeded by
Yoruba-bo rn Olusegun Obasanjo, who is the present Nigerian
head of state.
Government
One of the most welcome acts of Gen. Murtala Mohammed
before his assasination was the creation of a union of
nineteen s tates* out of the twelve which Gowon had created.

;~eca~se t here have been no significant developments in

s~~~ria~s sev en new states since their creation, the twelvethes~ s ruc ture will be used throughout the length of this
18,
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Nigeri a is presently under a military regime headed by
Lt. Gen. Olusegun Obasanjo.

The Supreme Military Council

is the mos t powerful policy-making body in the absence of
a legislat ure .

The Federal Executive Council performs the

role of a Cab inet .
Except t hat decrees promilgated by the Federal Military
Government are beyond judicial review, little has changed
in the Federal and State judicial systems since the days
of civilian governments.
Barring other significant military uprising, it is hoped
that the present government will hand over the administration
of the country to the civilians in October, 1979, as planned.

III.

MEDICAL AND PHARMACEUTICAL PROFILE

The People's Health
In Nigeria where the life expectancy at birth is 39
yearsl compared to 71.9 years 2 in the United States, it can
be said quite succinctly that the health of the people is
not good.
Like in most developing countries of Africa, Latin
America and Asia, major causes of morbidity and mortality
are due to afflict·ion with preventable diseases such as
malaria, tetanus, measles, tuberculosis and meningitis.
These diseases along with small pox,

11

whose eradication

in Nigeria by 1980 is considered feasible," dysentary and
cholera account for 95 percent of all ill health and deaths
in Nigeria by 1974.3

Malaria is the most notorious and re-

mains the most intractable problem because of the wide
exposure of the population to the vector-mosquite.
Table I is a list of Nigeria's leading causes of illhealth and death.

It represents those cases that were reported

between 1968 and 1972.

It can be seen from this table that

much of Nigeria's ill-health and death is caused by preventable diseases, most of which are under control in the
United States.
The figures in this table may be quite deceiving.

The

reported cases are those that occur in cities where facilities

TABLE 1

REPORTED CASES AND DEATHS FROM NOTIFIABLE DISEASES (1968-1972)

1968
DISEASES

CASES

1969

DEATH

CASES

1970

DEATH

CASES

1971

1972

DEATH

CASES

DEATH

CASES

DEATH

NA*

NA

NA

NA

NA

NA

11404

3095

1363

96

Small Pox

1832

164

186

20

79

1

NA

NA

NA

NA

Cerebrospinal
Meningitis

1879

214

4291

459

9712

1077

7897

886

5254

604

Tuberculosis

8952

274

11710

214

33279

577

19344

257

17584

282

Malaria

265908

265

369397

413

628534

1109

644494

613

798344

517

Measles

49947

811

45139

610

53529

449

88722

785

84495

495

Tetanus

1177

323

1689

414

3035

639

2360

462

2707

694

Cholera

*NA = Not Available .
Source: Federal Ministry of Health, Statistics Division , Lagos, Nigeria. 1974 .
......

.

-..J
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are usually available - and as will be seen later, the number
of such cities is very small.

Several thousand cases occur

in villages and towns that are far from urban areas and
hence cannot be reported.
Shortage ef Health Manpower
In the period between 1962 and 1972, the number of
physicians in Nigeria rose from a scanty 1,354 to 3,112, representing a doctor to population ratio of approximately
)1100,000 in 1962 and 51100,000 in 1972. 4 Though this
represents an increase of more than 100 percent in the 10
years period, it has not yet met the standard of 101100,0005
set by the World Health Organization (WHO) for this part of
the world.
The situation is even more critical when consideration
is given to the 1 , 280 or 41 percent of the physicians who
are expatrates.6

Corresponding ratios for dentists in this

period were 1:931,000 in 1962 to 11548,000 in 1972;* a
ratio of much less than 11100,000 people.
The figure for pharmacists is even more critical.

In

1962, using figures of Nigeria's Ministry of Economic
Development, there were 583 re g istered pharmacists in Nigeria
{including non-practicing pharmacists).

Ten years later,

there were 1,005 registered pharmacists or a ratio of
approximately 1:100,000.

*See Table 2.

TABLE 2

HEALTH MANPOWER IN NIGERIA (1962-1980)

YEAR

POPULATION
MILLIONS

*N

1962

1972

1980

54

69

81

ABSOLUTE*
FIGURES

PER
100,000

ABSOLUTE*
FIGURES

PER
100,000

ABSOLUTE*
FIGURES

PER
100,000

1,354

2.5

3' 112

4.5

5,760

7,0

.58

0.1

126

0.2

202

0.3

.583

0.9

1,005

1. 5

2,025

2.5

7,105

13.0

15,682

22.7

16,730

33.0

Radiologist

68

0.1

124

0.2

810

1. 0

Med Technologist

71

0.1

240

o.4

810

1. 0

HEALTH MANPOWER
Physician
Dentist
Pharmacist
Nurse

+Population has been adjusted yearly, using 1963 as base year; 2.7 percent population
increase per year (WHO's estimate) 1963 census (55.6 million).

*

Figures obtained from Federal Ministry of Economic Development, Statistics Division
page 263.

All other figures are extrapolated.

......

'°.
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Using WHO's World Directory of Schools of Pharmacy, 1966,
a comparison can be made between the United States and African
figures, particularly that of Nigeria.

In 1963, there were

9 ,600 pharmacists in the whole continent of Africa, excluding
the country of South Africa. At this time African population
was about 296 million.

This represents a ratio of 31100,000.

There were only thirteen colleges of pharmacy in the whole
continent.
Nigerian population at this time was 55.6 million (1963
census).

There were 484 actibe pharmacists in the country

and one college of pharmacy.

In the United States at this

time, there were 117,897 pharmacists and a total of 76 colleges
of pharmacy.

The United States p9pulation at this time was

about 192 million.

Expressing this figure in number of

pharmacists per hundred thousand population, Nigeria had
three in 1962 to six±y-three in the United States in the same
year.
While in 1972 the number of pharmacists in the United
States was 132,959, an increase of nearly 13 percent over
1962 figures, and a ratio of 63:100,000; Nigerian figures
were more than doubled to about 1,300 but remained at an
incredibly low rate of 2:100,000.
To bring these figures a little closer home, Rhode Island,
the smallest state in the United States, with a population
of less than one million in 1972 had a pharmacist to population
ratio of 83:100, 000, even surpassing the entire United States
ratio of 63:100,ooo.7
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Distribution of Health Manpower
Of even greater concern is the gross inbalance in the
distribution of the available manpower.

Only 16.7 percent

of the entire population lives in urban areas of 20,000 or
more.8

Most of the health care personnel live in those areas.

Indeed, in this student's home town of Ondo in Western States,
which has a population of about 100,000, he knew of only two
physicians.

One of them was in the only General Hospital

in Ondo and the other was engaged in private practice.

There

were only t wo pharmacies and perhaps two or three patent
medicine stores.
In state capitals and in larger cities there is an overconcentration of health care personnel much as in the United
States bigger cities.

While the overall physician/population

ratio in Ni geria is approximately 41100,000, in some states
the ratio could be as low as less than 11100,000.

Since

there are no records of state by state distribution of all
physicians in Nigeria, it is being assumed that the distribution
of state-employed physicians as illustrated in Table 3, reflects the distribution of all physicians in Nigeria.
Moreover, 57 percent of all physicians in Nigeria are employed
by the states or the Federal government.9

Estimating these

figures from those shown in Table 3, it can be seen that it
ranges in density of 24:100,000 in Lagos State to as low as
less than 1:100,000 in North-Western State. It can be seen
that th e six southern states of West, Lagos, East-Central,
Mid-West, and Rivers (except the South-Eastern State) account
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TABLE J
DISTRIBUTION OF STATE EMPLOYED PHYSICIANS (1972)

STATE

(MILLION)
POPULATION*

NUMBER OF
STATE-EMPLOYED
PHYSICIANS

13.7

494

4

NUMBER PER+
100,000 PEOPLE

1.

WESTERN

2.

LAGOS

1.9

464

24

J.

EAST-CENTRAL

9 .23

280

3

4.

NORTH-CENTRAL

3.1

114

4

5.

MID-WESTERN

3.1

106

3

6.

NORTH-EASTERN

9.8

60

1

1.

KANO

7.2

53

1

8.

BENUE-PLATEAU

5.2

47

1

9.

SOUTH-EASTERN

4.1

46

1

10.

RIVERS

2.0

44

2

11.

NORTH-WESTERN

7.1

J6

1

12.

KWARA

J.4

JO

1

1774

4

*Ex~rapolated from 1963 Census given in Africa, No. 44,
April, 1975. p. 2J
+Approximate Figures.
Source:

IMS WORLD DRUG MARKET MANUAL, SEC. 14.1, 1975
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for approximate ly 78 percent of all physicians in Nigeria.
According to the 1963 census, cities and towns in
Nigeria with population above 70,000 are thirty-eight.
twenty of these are from the Western State.10

In this

state there is Nigeria's second most populous city - Ibadan.
With a population of 1.5 million and also serving as the
state capital, it has nearly all the Western State ;establishments and therefore has the majority of all practicing
physicians.

Lagos, the Nigerian capital, population 1.8

has nearly 28 percent, the highest concentration of all
physicians in the entire Federation of Nigeria.
The effect of these figures is to demonstrate a critical
shortage of physicians in the six northern states of Nigeria,
which together form more than 60 percent of the entire
population.

With the exception of North-Central State which

has a ratio of 4:100,000, all the other northern states
have well below the ratio of 1:100,000.

Kaduna, a city of

300,000 people has the greatest concentration of practicing

physicians.

Kaduna, of course, is the capital of the North-

Central State.

This maldistribution is also true of all the

health care personne l.
alike.

It is true of dentists and pharmacists

The maldistribut ion of health personnel is not unique
to Nigeria only.

we11.

It is a problem in the United States as

Washington D.C., a city of well over 700,000 people

had the highest concentrati·on of active physicians
· ·
· t he
in
United States in 1967.11

It had a physician to population
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ratio of 31 8 1100 , 000.

Washington D.C. of course, is the

capital of the United States.

Next to this is New York State

with 199, Massac hussetts with 181, Colorado with 168, and
Rhode Island, wi th a ratio of 1511100,000.

On the other

end are the state s of Alaska with a ratio of 69, Mississippi
with 69; the Commonwealth of Puerto Rico with 68 and the

u.s.

outlying areas with a ratio of 611100,000.

It is common

knowledge that there is a propensity for higher concentration
of active phys i c i ans in state capitals and of course, in
the Federal Capital as has been seen in the Nigerian figures.
The same is true of all other health professionals.
Medical Facili ties
Health care centers are basically located in state
capitals and few in the large cities.

As of 1973, there were

399 hospitals i n Nigeria, distributed disproportionately,
just as health care personnel were.

To compliment these

facilities are 130 maternity homes and child centers; 1,600
dispensaries whic h provide a combined total of 4,920 additional beds. 12

As is the case with the staffing of these

facilities, the inherent problem of maldistribution exists.
The rural areas are the most badly affected, and in some rural
areas where there are facilities, services are usually "lopsided, leaving l a rge urban areas without medical attention. 111 3
The Third Deve l o ment Plan

1

Health

The deve l opment plan is certainly the most comprehensive
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of all health plans ever made in the history of Nigeria .

Top

priority is given to the "development and expansion of relevant
training institutions in the country to ensure the adequate
supply of the needed cate gory of health manpower and their
even distribution in the country." 14

An admission rate of

about J,000 a year into Nigeria's medical schools is planned
tor 1980.

It is the government's plan to establish Teaching

Hospitals in all state capitals in order to have an even
deployment of physicians and the para-medical personnel
such as pharmacists, laboratory technicians, nurses, etc.
Emphasis will be placed on preventable health services
such as improved sewage systems, improved drainage systems,
and improved environmental sanitation.

A total of N760

aillion ($912 million) is budgeted for the plan period.
lorty-one percent of

this amount has been allocated for

Federal programs and the rest for state programs.
Seeking Medical Help in Nigeria
Nigerians usually go through three stages in the process

Of seeking medical attention during sicknesss
1.

Self Diagnosis and Treatment - Self diagnosis and

treatment involve s several mythical phenomena which are
transfered from generation to generation.

The problems

treated in thi's manner range f rom impo
·
t ency t o sc h'izop h renia.
·
Concoctions are made from leaves and tree barks and are usually
mixed with alcohol (for better extraction).

The dosage

~egimens are irregular and lack specific measures.

But the
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people have confidence in it

~nd,

apparently, it works; they

often het healed.
2.

Native Doctors (Herbalists) - The native doctors are

in line after the process of self-diagnosis and treatment has
failed.

If the problem continues unabated, it is perhaps

one brought on the individual by an angry god or a distant
jealous relative.

The herbalist is consulted and his re-

commendations are highly esteemed.

A herbalist has been known

to perform simple scientific experiments in the process of
the diagnosis of diabetes mellitus.

He asked his patient to

urinate in one corner of his room, after a period of about
10-15 minutes, he would check the spot for ants.

A cluster

of ants on the urine would suggest the presence of sugar in
the urine.

He would then taste the urine to confirm the

experiment.
The herbali st is usually not educated, but has some
attributes which are essential for the job.
is not limited to the following:

It includes, but

religion, sacred and acrobatic

dances, simple magical charms, incantations, drug lore,
mythology and etc.

Bundukamara15 likens these qualifications

to those of the primitive medicine men of the Navaho Indians
of the South-West United States.

The more charms and incan-

tations the herbalist knows, the more likely he is successful
in his practice.

A long period of apprenticeship is a must

fer the potential herbalist.

He associates with an older and

•ore experienced herbalist and runs errands and does a lot
Of the compounding of the various ingredients in his pre-
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ceptor's "pharmacopoea".

In this process, he picks up the

incantations and charms that form a major integral part of

the medicinal practice, and soon he becomes a herbalist himself.

According to Kouadvi,16 " ..• the art of healing is

limited to various categories of people who inspire respect,

tear and mistrust, '1 with reference to the herbalists.

These,

in a few words, explain the qualification of the Nigerian
native doctor.
Kouadvi's list of African Traditional Pharmacopoea con•ists of the following:
(a) Simple or compound species - made with mixtures of
leaves or barks;
(b) Packages - made of leaves of trees or papers;
(c)

Plant ~ juices

- obtained by grinding after squeezing

fresh plants;
(d) Alcolature - obtained from roots and barks which
have been macerated in gin, rum or any other alcohol;
(e} Pellets and pill - pounded fresh leaves rolled into
balls of desired size and dried;

(f} Liniments - made of oil from palm trees, cocoa, sesame;
(g) Throat sashes - mixture of astringent plants or an
infusion of such plants.
Contusion, grinding, separation, squeezing, torrefaction and
carbonization are used in the process of compounding these
terials.l?

Scientific accuracy is not necessary and thera-

P9Utic application of these materials vary depending on the
ntu·t·
1
ion of the herbalist.
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A sick man, down for example ranging from simple bacterial
infection to complications of cancer, is treated in part, with
rituals such as invoking the power of the gods , and asking
the patient to repeat certain incantations three, seven or
twenty-one times, depending on the seriousness of the disease.
Directions to patients often inlcude a list of taboos, the
violation of which may nullify the effect of the preparation.
This is analogous to the practice of the Cherokee Indian
tribe of North America, whose taboo list include the following:
• ••• one must not touch a squirell , a dog, a cat, a mountain
trout, a woman •... " l 8
Eric Stone's19 classification of American Native "materia
medica" into three categories can be applied to Nigeria 's
medicine men of today:

1.

Substances effective as carriers of devine power for example, the Apache relied on a piece of cholla
cactus hung around the neck to protect children
against sickness, just like the American grandmothers used a tiny bag of asafoetida to protect
their children.

2.

Substances upon which "God" had put a sign as to
their intended usefulness - for example, the
Hopi used hair-like clematis fibers to treat
falling hair, and dusted ashes on burned skin
as a healing protective .

3.

Substances used for their physiologic actions
(empirically discovered) - the Missouri River
tribe used wild mint as a carminative and
magnesia salt found in mineral springs as a
laxative.

The power of the Nigerian native doctor is immeasurable.

Stor·
ies have been told of persons whose magical power makes
them "disappear" at the sound of a gun shot, military officers
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who can catch f lying bullets and executives whose jobs become
•secure" aft er a visit to the native doctor.

Judges are said

to have slept and snored in the midst of complicated criminal
trials as a re sult of magical charms cast on them by the
accused.

Such court cases are said to have been dismissed

after several such incident!
Belief i n the native doctors is diminishing gradually as
Nigerians are bec oming increasingly aware of the scientific
approach to dise ase healing .

Less confidence is placed on

the native doc t or ' s empirical approach.

Illness is blamed

less on the doing of distant relatives or jealous subordinates.
More and more people are turning away from them as Nigerian
Lawmakers are pondering on what to do with them.

There have

been calls fo r t he legislators to ban them from practice.
Opponents have argued that this would be disastrous especially
tor people in t he rural areas where physicians are inherently
absent.

Others have called for their certification.

But it

is difficult to certify a native doctor ' s credential without
baving a measuring yardstick on his abilities and capabilities.
Many scient ists, including Dr. Adeoye Lambo,20 an
•inent psyc hi a t rist with international repute, have called
for a joint ve nture between the native doctors and Nigerian
•cientists in r esearch into African Medicine .

The Nigerian

Association of Medi· cal Herbalists ( a group representing the
l'll.tive doctors) has siad that it would like to see the developent Of tradit ional medicine side by side with modern methods
Ila in China and Egypt.

It said that a ban on their practice
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•

will cause hardship to millions of Nigerian patients
21 This
and increase the death rate significantly."
•••

statement is further reinforced by the statement of the former
Mid-Western State Governor - Brigadier Ogbemudia, who urged
the Nigerian Medical Council to conduct research into
tradtional medicine.

The North-Central State Governor also

supported the idea of conducting research into local herbs.22
While the traditional healers occupy a very unique
position in Nigeria's health care system, the prognosis for
their continued existence in this role is not very good.
Gradually their role is being phased out; not by the Government (which is a more effective way but certainly more controversial2, but by the people themselves who have identified
a better and less primitive system.

Thus, the elimination of

their role from the health care team is only a matter of time.

3.

Pharmacists and Physicians - The third and final .

step in seeking medical help in Nigeria is a visit to the
Pharmacist or the physician.

The position of the pharmacist

in the heal th team is very important.
just as Bundukamara23 pointed out.

He is a "Quasi-doctor"~

He is sandwiched between

the practice of pharmacy and the practice of medicine,
whereas, in the United States, the pharmacist serves as a
•iddleman between the patient and the physician.

As far as

drug consumption is concerned, the relationship between
P8.tients/pharmacists/physicians in Nigeria is a rather more
8Ubtle one.
Most patients do not see a pharmacist after a visit to
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the physician.

A lot of them do not see the physician after

a visit to the pharmacist either.

own prescriptions . 24

Physicians dispense their

Several reasons can be conjectured for

this practice:
1.

Physicians dispense their own prescriptions because
of the profit obtained from selling those drugs
themselve s;

2.

Because of the esteem derived from doing so - most
Ni gerians believe in the physicians power of healing
and cannot conceive of the idea of going to a third
party to obtain their medicines;

J.

Patients usually feel that physicians have not done
their jobs properly if they do not receive medication
from them;

4.

Physicians have 100 percent control over their patients.

Other reasons would shed some light on the practice of some
of the Nigerian pharmacists:

5.

Most physicians believe that their prescriptions are
dispensed by persons other than pharmacists whose
" •.. knowledge of medicine is only limite to the
name of the package or the bottle. 11 25

6.

Because of the 11 • • • unscrupulous pharmacists who
would sell deadly and untried drugs which they
profess to be potent and efficaceous at factastic
prices. 0 26

7.

Some physicians have argued that" ... they would
rather dispense than send prescriptions to shop
assistants .... Since pharmacists are not there
most of the time in the part-time shops ... 27
11

If these charges are true, it is a serious indictment on
he integrity of many Nigerian pharmacists.

Looking at the other side of the issue, pharmacists in
Nig ·
eria may be engaged, to some extent, in the practice of
•dicine. 1 n a Lagos University Survey of 1,000 consumers,

31.
percent acquired their last medication from a pharmacist
30
without a phys i cian ' s prescription.28 Apparently , pharmacists
prescribe drugs to their patrons in contravention of legal
dictates and ethical standards.

It is unfortunate that the

study failed to identify what category of drugs this fraction
of those questioned have obtained from their pharmacists.
This survey, however , supports pharmacists' claims of professional competence , and their desire for better recognition

of what their capabilities are .

Apparently, the

JO percent

who responded obtained relief from whatever patholog ic problems they had, or they would have had to go to the physician.
The syrvey als o underscores the importance of the pharmacists

in a developing c ountry where the economy cannot affort the
"luxury" of physician attention .
The physicians ' charges against pharmacists - that
pharmacists do not dispense the prescriptions sent to them,

is also a serious issue.

The implications are obvious.

Pharmacists simply keep their pharmacies open and leave the
premises to be manned by non-professionals.

Physicians

resent this pr ac tice and therefore stock their offices much

as pharmacists would stock their pharmacies, and di s pense
their own prescriptions in direct competition with pharmacists.
This raises the question of the integrity of the physicians
too.
The possib ility of prescribing and dispensing only
drugs that are s t ocked exists; in essence, setting up a
superficial f ormulary.

It is
· no t k nown wh e th er or no t , and

J2 .
in what rate if at all, physicians direct patients to pharmacists to obtain drugs that the physicians do not normally
stock.

It has b een suggested however , that the lust for

money may i nde ed force the physician to limit his prescribing
habit only to drugs that are stocked whether or not they are
'the most appropriate for the disease diagnosed .
All this cont roversy revolves around a basic flaw in
the Nigerian system :
1.

The enforc ement mechanism of laws enacted re garding
the control of the professional practices of these
groups is nothing but an illusion.

2.

The laws enacted are not adequate for the control of
these professions .
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IV. EVOLUTION OF PHARMACEUTICAL LAWS AND PRACTICE:
UNITED STATES AND NIGERIA
Just as t he American criminal and tort laws are an outgrowth of the British Common Laws. so are the pharmaceutical
laws enacted i n Nigeria. in some ways an outgrowth of British
pharmaceutical laws.
Nigeria enj oys the unique opportunity of not only
emulating the British system, but emulating the American
eystem as wel l i n their judicial systems.

West Africa 1

reported that the present draft of the Nigerian Constitution--

due to be ratified by a Nigerian Constituent Assembly in 1978,
will in theory. be similar in many ways to the United States
Constitution.

Ni gerian pharmaceutical laws have followed

this pattern consistently.
Evolution of Pharmaceutical Laws in Nigeria
Richard Z. Bailey was granted a license to open a pharmacy

1n Lagos in 1887 ,

This, according to Egboh2 marked the entry

into Nigeria of European Pharmacy . Thelaw requiring examination
and l'icensure of pharmacists was enacted in London in 1617 3
and apparently was found fit for Nigeria, a country witnessing

the entry of its
·
first pharmacist.
Just as pharmacists served a period of apprenticeship
llnder the physic ians in the United States, the Nigerian
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"dispensers" of this time served under the supervision of
the British Medical Officers.
Pharmacy Ordinance No. 8 of 1902 marked the beginning
of pharmaceutical regulations in colonial Nigeria.

It was

designed to control the sale and distribution of drugs along
the coastal areas of Nigeria.

The term "dispensers" was

discarded in the Act of 1923, when the term "druggist" was
adopted.

It was thought to be more prestigious and more

reflective of the three year training course started at the
newly constructe d School of Pharmacy in Yaba, Lagos.
The Poison and Pharmacy Act of 1927 provided for instruction 0f students for the "Dispenser's Certificate".
Further studying would earn a Chemist and Druggist Diploma.
Examinations were conducted by the Medical Supervisory Board.
Just as there was controversy over the professional
atatus of pharmacists in Britain in the 1600s and 1700s,
there was also a delay in the recognition of pharmacists
in Nigeria as professionals.

Until 1969, remuneration of

Jtharmacists was based on a classification of pharmacy at a
ub-professional level.

This was changed in 1969 on the

recommendation of Professional Grading Team commissioned by
Nigeria's Military Government.
In 1936, the Poison and Pharmacy Ordinance was enacted
bring pharmaceut ical education in Nigeria in line with

'\hat of the United Kingdom.

The syllabus and curricula of

he Ch emis
· t s' and Druggists' Diploma were standardized and

body known as the Pharmacy Board of Nigeria was created

37.
out of the representatives of the Nigerian Union of Pharmacists
and the Association of Dispensers.

This body is now known as

the Pharmaceutic al Society of Nigeria.
The 1936 Act also set up rules regarding the granting

of licenses for thesale of patent and proprietary medicines,
and also required the issuance of the Missionary Permits for
dispensers who practice at missions.

This Act reflects the

level of sophistication of the Nigerian Pharmacy then and subsequent Acts are even more comprehensive, particularly in
dealing with the expanding level of pharmaceutical service
in Niger is.
In 1946, there was an ammendment to the 1936 Ordinance
repealing that requirement for the dispensers examination

and strengthening the establishment of the Pharmacy Board of
Nigeria with the medical adviser as the Chairman.

It also

gave control and disciplinary powers over the practice of
Pharmacy in Nigeria to the Board.
Following the 1946 Act came the Ordinance of October 1960,

ihe year of Nigerian Independence, which is termed the Poison

!Dd the Pharmacy Act of 1960.
What Egboh4 termed the "magna carta" year of Nigerian
Pharmacy was in 1964 when the control of the profession was
118.de the responsibi lity of the Pharmacy Board of Nigeria.

the chairmanship of the Board was handed to the Chief Pharmacist of the Federation of Nigeria.

The Pharmacy Act of 1964

•lso made provi· s i· ons for th e determination
·
·
o f '' wha t s t andards''
•f knowledge
and skills are expected" from prospective pharmacists.
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The year 1966 marked a turning point in Nigerian history
as the Army took over the adminstration of the country.

All

enactments heretofore called Ordinances are known as Decrees.
Most of what Nigeria now has as drug laws were enacted
during some eleven years of military rule in Nigeria.

The

Indian Hemp Decree is perhaps the most stringent law on book
in Nigeria.

It was promulgated as a result of growing use of

JIB.X'ijuana in the country.

It decrees a t wenty-one year jail.

or death sentence for the possession or intent to distribute
marijuana in Nigeria .
The Amphetamines Decree of 1968 was enacted to control

the use of amphetamines and amphetamine-like drugs in Nigeria.
It also prohibits the use of and imposed strict penalty for

the use of Lysergic Acid Diethylamine (ISD) and some other
narcotic drugs.
The most comprehensive law enacted to control the
iaharma.ceutical industry in Nigeria is the Food and Drug Decree
Of 19?4.

This law reflects the trend in times as it deals for

the first time ever with the control of manufacture of drugs .
~t also deals with various aspects of drug marketing which

eretofore have not been dealt wi th.

It deals with the ins-

pection of the premises used for manufacturing drugs. and for
the f'irst time, there are provisions for the control of
lla.nutacture, distribution and marketing of devices.
Evolution of Pharmaceutical Laws in the United States
Pharmaceutical laws were not enacted in the United States
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til the "Virginia Act for the regulation of the fees and
llccounts of the practicers of physics"5 was passed in 1736.
this time, the rates allowed those persons "who have
atudied physic i n any university and taken any degree therein
•• " wer e about t wi ce as high as the fees allowed:

"

...

surgeons, and apothecaries who have served apprenticeship for
'hose trades ... "6

For the protection of patrons against

high fees charged by physicians and apothecaries at that time,
the law stressed t he need for complete disclosure of all drugs

spensed to the patients and also that moneys charged must
reflect the quant ities of drugs dispensed.
At about the same time, the Massachussetts Medical Society
fetitioned the l egislature to "prohibit the sale of bad or
adulterated drugs."

Louisiana and North Carolina laws

established the princ iple of licensure as prerequisite for

e practice of pharmacy.

In 1821, the Philadelphia Colleg e

o:t Pharmacy wa s established as a protest a gainst the encroachllent of the medic al profession in the profession of pharmacy.

The first s ecretary of the American Pharmaceutical
sociation (APHA) , John M. Maisch, suggested uniform state
)iilarmacy laws i n 1868, and in 1900, pharmacist/lawyer James

K Beal vigorously promoted the passage of such laws.
As retail pharmacy expanded in the U. S ., so did i nterest

in drug manuf acturing; and as new drugs were introduced into
'1le Am erican
·
market , it became necessary to enact laws to
b the laissaz-faire attitudes among manufacturers a nd
•llers 0 f
.

proprietary medicine s.

It was necessary t o enact
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the fure Food and Drug Act of 1906 which was desi gned to enact
penalties for c ertain types of misbranding and adulteration . 8
!he disaster of the "elixir sulfanilamide" of 1937 which
killed at least 73 people, and the public demand for protection
against the unscrupulous practices of the pharmaceutical
industry, force d the congress to pass an even tougher leg islation in 1938.

This was the Food, Drug and Cosmetic Act

which imposed ce rtain restrictions on the marketing of "new
drugs".

It a lso gave the Federal Government jurisdiction

over medical devi ces and cosmetics .

At the same time, congress

passed an ammendment to the Federal Trade Commission Act in
order to put effective control over false advertising of
foods, drugs and cosmetics and over deceptive and unfair
trade practices . 9
The thalidomide episode of congenital malformation reported in Europe and Canada in 1960 and 1961 precipitated
the passage of t he Kefauver-Harris Ammendment to the 1938

Law.

This ammendment added the safety clause to the efficacy

requirement fo r a new drug to be approved for marketing .

It

is perhaps the single most effective leg islation passed in
Congress to control the introduction of new drug s into the
United State s market.

It curtailed, rather sharply, the

introduction of new drugs in the United States.
The Food and Drug Administration (FDA) imposes strict
req uirements
·
on drug companies before drugs can be approved
tor marketing by the following :
1.

requiring extensive testing to demonstrate safety
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and effectiveness.
2.

requiring that companies continue to submit periodic
reports on their drugs during marketing.

3.

putting restrictions on advertising and other forms
of promotion during marketing.10

Analysis of Significant Developments
With the exception of the Food and Drug Decree of 1974,
no other laws of significance have been enacted to control
the practices of the drug manufacturers in Nigeria .

It was

not necessary to do so because of the absence of drug manufacturers in Nigeria.

This parallels the situation in the

United States during the colonial period under the United
Kingdom.

Drugs generally were imported from Great Britain,

and what was right for the U.K. at that time was considered
right for her possessions.
However, since independence in 1960, several British
companies, such as Glaxo Pharmaceuticals, May and Baker,
started to do some manufacturing in Nigeria.

During the mid-

1960s, some American companies started a small scale manufacturing in Nigeria, and it thus became necessary to set up
guidelines . for the operation of their business as it impacts
upon public health and safety.
The evolution of pharmaceutical practice and laws has
taken similar paths in both countries.

The pharmacy profession

was subJ.ected to intense pressure by the medical profession.
Although Nigeria witnessed the entry of its first
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pharmacist nearly 100 years ago, it did
as a profes s i on until 1969.

not recognize pharmacy

Even now in the United States,

the status of the pharmacists is under challenge .

The United

states pharma c ist during the 1800s became militant enough
to break away f r om the shadows cast on them by the medical
profession to form the first professional organization -the American Pharmaceutical Association .
In most cases , drug laws have eveolved in the United
tates thro gh a national or international tragic experience
from drug toxic ity or adverse effects.

In Nigeria, particularly

before the military era , drug laws developed through evolutionary mens and through international influence.

But

since the begi nning of military rule in 1966, drug laws have
evolved through radical efforts of Nigerian legislature, and
aore important ly , from examples set by other nations, particularly the Uni ted States.
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V.

GOVERNMENT CONTROL

A Comparison of Selected

As~ects

of United States and

Ni erian Pharmaceutical Laws.
As consumption of drugs rises each year in Nigeria, and
as the nation' s economy develops in massive proportions (per
capita consumption of drug is still about $1.00 compared to
$JO.CO in the United States in 19751 and the Nigerian Gross
National Pro duct (GNP) was about $27 billion2 compared to
United State s $1,400 billion in 1975), more and more pharmaceutical companies are finding their way into the Nigerian
market.

And as the scramble for the Nigerian market continues,

the Nigerian Government is imposing more restrictions on
business activities of foreign companies in Nigeria.
The Indigenization Decree Ammendment of 19773 classified
all busines s activities into three cate gories:
1.

Schedule I:

Those business which are

exc~usively

reserved to Nigerians.
2.

Schedule II:

Those business which allow 40 percent
foreign participation and

J.

Schedule III:

Those business that allow 60 percent
forei gn participation.

The Pharmaceut ical industry is grouped in Schedule III.
In the United States, several government agencies are
given the statutory authority to control the distribution of

drugs.

Chief among these is the Food and Drug Administration

(FDA) which controls the marketing and promotion of prescription drugs.

It also shares in the responsibility for the

control of the promotion of over-the-counter drugs with the
Federal Trade Commission (FTC). 4

The FDA inspects manufac-

turing faciliti es, reviews and approves or denies the clinical
testing of drugs prior to marketing; limits the therapeutic
claims for products and monitors advertising.

Recently the

FDA embarked on a major scientific examination of the medical
credentials of prescription drugs on the market.5

Other

government agencies involved in the control of the distribution of drugs are:

The Drug Enforcement Administration

(DEA) which is responsible for control of drugs with misuse and

abuse potential, and the Division of Biologic Standards (DBS)

which controls the distribution of Biologics.
In Ni geria , there is only one agency designated by the
•ilitary government which controls the activities of the drug
industry in areas of manufacturing , distribution, promotion
and

advertising .

ouncil (FDAC).

The agency is the Food and Drug Advisory
Its function is to formulate guidelines in

the following areas:
(a)

Determination of adulterants

(b)

Packaging, labelling specifications and sale

(c)

Preventing the consumers and users from being misled
by manufactures as to the value of the ingredients

(d)

Laying down standards to be attained by articles

(e)

Importation

46.
(f)

Manufacture, preparing, packing, storing and testing
of articles

(g)

Maintenance of books and records as prescribed

(h)

Application and issue of certificates to qualified
manufacturers and conditions required of the premises
where manufacturing will be undertaken

(i)

Acquisitions of test batches of drugs manufactured
to ascertain their suitability and paying the
prescribed fees

(j)

Mode of sampling reporting

(k)

Exemption of certain materials from the provisions
of the Act

(1)

Prescription of the forms to be used

(m)

Conducting analysis and prescribing fees for such
analysis

(n)

Distribution of samples of any drug

(o)

Ammendments of the schedules as may be necessary

(p)

Prescription of other things for the execution of
this Act .

These functions are shared among other sub-agencies under
The sub~agencies are as follows:6
1.

Federal Manufacturing Laboratory

2.

The Federal Medical Stores, Oshodi

J. The Kano Airport
4.

Pharmaceutical Registry and

5.

The Inspectorate Unit.
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The Federal Manufacturing Laboratory does not presently
_.nufacture drugs as the name implies, but there is a plan
extend the existing laboratories to increase the production
f simple and cheap drugs for use in government hospitals.

The FDAC is headed by the Chief Pharmacist of the
ederation who is responsible to the Minister/Commissioner for

Several areas of comparison exist between the Drug Laws

of Nigeria and the United States and they will be explored
detail under the following titles:

Product Standards,

icing, Distribution and Restrictive Sale and Promotion and
Comparison will be made between the two systems
d major differences will be identified.

roduct Standards
The United States, through the Food and Drug Administration

(FDA), establishes standards of safety and efficacy through
a battery of pre-marketing testing which almost entirely
the possibility of marketing products which are
human consumption.

Pre-marketing testing is done

as required by the provisions of the "Notice of
laimed Investigation New Drug (IND).

Pre-marketing testing

by the provisions of the New

Before the application for the IND is filed with the
assumed that all details about the pharmacology,
bio logy, etc. of the new drug product, have been
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The next step is to apply this knowledge in clinical
beings.
The New Drug Application requirement is in three phases:

A period of human pharmacology, when investigations are
to indicate toxicity, dosage, absorption, excretion
in the body.

A period of limited trial of the drug in patients with

the disorder the drug is designed to treat.
Phase III:

Large scale trial on patients with the specific disorder.
estimated that it takes at least sever-and-a-half
Pharmaceutical Manufacturers Association - PMA said 10 years) from the period of gestation of a potential
drug to final approval of the drug for marketing by the FDA.

If tlEnew drug is an antibiotic, the FDA laboratory assays it
determine that it has the required potency and safety and

hat it meets certain other standards of quality.

Each batch

et antibiotic produced must be so certified.a
Before the 1961 thalidomide disaster in parts of Europe
Canada, only a safety requirement was imposed on new drugs

tn the United States .

After the disaster, efficacy requirement
provisions of the Kefauver-Harris Ammend-

1962.

This ammendment also, for the first time pro-

definition for "new drugs".

In some instances, the Food, Drug and Cosmetic Act of 1938
similar to the Nigerian Food and Drug Decree of 1974 which
~empts al l drug laws e nacted in Ni geria before 1974 .

Para-

traPh 7 of t he Decree reads a s follows :
No per ~ on ~hall manufacture ~or sale, a~y.drug
specified in schedule 4---- without obtaining
a certif i cate from the commissioner that the
premise s in which the drug is intended to be
manufactured and the conditions by and under
which the manufacture is to be carried on
are---sui table for ensuring that the drug
will be s a fe for use . 9
Jlaterials list ed in schedule 4 are as follo ws:
Liver Extra c t in all forms
Insulin in all f orms
Anterior pituitary extracts
Radioactive isotopes
Living va cc ines for oral or prenteral use
Drugs prepared from micro-organisms or viruses , for
patenteral use
Sera and Drugs analogous thereto , for parenteral use
Antibiotic s for parenteral use .

As seen in the above list , some of them are biologicals, some

are biolog ica l extracts , one is a radioactive isotopes and
•ome are ant i b iotics .

is on the

11
•••

The emphasis in the above regulation

premises in which the drug is intended to be
It can be noted that the safety of the

drug as regards its toxicity has not been mentioned .

The

requirement i n t he above regulation has been modified in
of the Decree which will be discussed below.
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The implic ation of the above law is that once the premises
which the drugs are intended to be manufactured are certified
the commiss ioner, the drug manufactured therein must be
Safe in the sense that the drugs do not contain
or filth" or any substance that would make them injurious
The toxicity of any drugs sold by the multicompanies is not at this time in question.
heir integrity is not being -,·impugned; their experience in
United States is enough to prevent any reoccurrence of
"Elixir Sulfanilamide" disaster of 1936.

However, the local

janufacturers, particularly the indigenous Nigerian drug
mpanies, operate within the same law.

This is where there

uld be potential problems.
Paragraph 7(2) of the Food and Drug Decree states as

No person shall sell any drug specified in
schedule 5 bf this decree without first obtaining
in accordance with the regulations a certificate
of the commissioner that the batch from which the
drug was taken is safe for use.11

5 are as follows:
Arsphenamine
Dichlorophenarmine Hydrochloride
Neoarsphenarmine
Oxophenarmine Hydrochloride
Sensitivity disc and Tablets
Sulpharsphenamine
ese are heavy metal compounds used as anti-infectives

or
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perhaps as anti-amebics.
in Nigeria.

These drugs are not used extensively

In fact, they are not used much in the United

States either.

However, they are subject to as much safety

requirements as are imposed on the manufacture of antibiotics
in the United States.

This might be due in part to the heavy

toxicity associated with this class of drugs.
It must be noted that this is the only group of drugs
subjected to such a requirement in Nigeria .

This is in

ontrast to the United States law which only restricts such
requirement to antibiotics due to possibility of variations
in the active ingredients from batch to batch during manufacture.

In Nigeria, antibiotics are not subject to such

a requirement.
The implication of this law is that all other drugs can
be manufactured in Nigeria without a proof of batch to batch
certification.

Antibiotics manufactured by United States

companies outside the United States are thus, not subjected
to this requirement as long as the sale of such antibiotic

in Nigeria would not be a contravention of the law of the
country of manufacture.
Paragraph 5 of the Food and Drug Decree states as
follows:
No person shall label, package, treat, process,
sell or advertise any food, drug ... in any
manner that is false or misleading or is likely
to create a wrong impression as to its quality,
character and value, composition, merit or safety. 12

The

Provisions of this paragraph may be subject to different

kinds of interpretati'ons depending
·
· d ividua
' ·
1s'
on each in
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interest,

Manufacturers may claim exemptions from the requirethe paragraph because of their apparent exclusion
provisions of the decree.

The government on the

other hand, can claim that the words "quality, character,
and value and merit" when taken tog ether and read in the
appropriate context , mean "efficacy'' or "effectiveness".

This decree is analogous in context to the Federal Food, Drug
and Cosmetics Act of the United States prior to 1962 when

only a proof of safety of drugs was the only requirement.
Effects of the Food and Drug Decree and the FDA Regulations
The Food and Drug Administration re gulations have a
significant impact on the activities of the Drug companies
in the United States, particularly in the periods after the

1962 Kefauver-Harris Ammendments.

Although the decline of

new drug introduc tions and in the new drug approval rate in
the United States cannot singularly attributed to the effects
Of the ammendments , it goes a long way in explaining such a

decline.

Table 4 shows the decline in the introduction of

Bingle new entity drugs in the United States from 52 in 1957

to 15 in 1975.

Table 5 shows a decline in number of total

•PProved NDAs in comparison to number of I NDs submitted.
In 1966, seven hundred and fourteen I NDs v. ere submitted

!4? of them reached the NDA stages and only 40 of them were
approved

an approval rate of approximately 21 percent.
one thousand one hundred and t wenty I NDs were

submitted, only 92 of them went to the NDA stages, and only
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TABLE 4
DECLINING NUMBER OF NEW DRUG INTRODUCTIONS (1957-1975)

Year

No. of Single
New Entity

1957

52

1958

47

1959

65

1960

50

1961

45

1962

24

1963

16

1964

17

1965

25

1966

13

1967

25

1968

12

1969

9

1970

16

1971

14

1972

10

1973

17

1974

18

1975

15

Pharmaceutical Manufacturers Association,
Presc ription Drug Industry s Factbook, 1976, p. 11
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TABLE 5
DRUG APPROVAL RATES IN THE U.S. (1966, 1970-1975)

SAR

TOTAL NO. OF
INDs

TOTAL NO . OF
NDAs

714

147

40

6

1120

92

51

5

938

99

62

7

976

297

57

6

913

146

50

5

842

106

85

10

818

132

71

9

TOTAL NO . OF
APPROVALS

PERCENT*
APPROVED

approval rate beginning from 1970 is 7 percent.
erage approval rate for the three periods requested in this
study between 1973 and 1975 is 8 percent.

•Percentage is calculated based on total number of INDs and
total number of approvals.
FDA Annual Reports and FDA unpublished data.
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•o of them were approved -- a rate of approximately four percent.
In 1975, eight hundred and eighteen applications were submitted,
l)2 of them reached the NDA stages and

only 71 of them were

a rate of 8 percent.
There is also a considerable decline in number of firms
operating in the United States from 127 in 1957 to 48 in

1968.13

It has been estimated that the existing multinational

companies will themselves grow and the increasing complexity

of research and the demand for higher standards of safety and
efficiency will raise the costs and encourage further amalpma.tions and takeovers.

"By 1990 worldwide pharmaceutical

research production and marketing will mostly be in the hands
f some one or t wo dozen companies.

About half of these will

originated from the United States."14
The present conditions in most developing countries and
in Nigeria which is the dominant force in Black
make it a fertile ground for pharmaceutical companies
nations,
The Hathi Committee15 has drawn up a list of essential
for the basic needs of India.

The list contains a

of 116 drugs which are considered to be adequate for

the medicinal needs of India.

This view is shared by Mayler

in his report published in the World Health Organizations
Monthly Chronicle as follows:
In many developing countries, the lack of national

~ru~ policies allows foreign pharmaceutical firms
0

influence the market demand to a considerable
extent and to control the transfer of pharmaceutical

56 .
technology when local production is undertaken by
their s ubsidiaries or under licensing agreements .
Furthermore , the regulations of the supply or
prices of raw materials greatly influences the
local pr oducti on of finished pharmaceutical products. Thw many developing countries remain
dependent on foreign interests and spend a high
proportion of their limited health resources on
imported f i nished products or raw materials for
local production of drug s, many of which are not
suited to t heir real health needs , 16
It is not known how many drugs are sold in Nigeria, but

f such a s t udy were conducted in Nigeria, the result would
probably be simi lar to India ' s .

It is estimated that only

I small proporti on of the order of one or two perc ent of the
in developing c ountries would be sufficient
cover basic pharmaceutical needs . 17

There are obviously

ch more than 116 drugs on the Nigerian market .
The price paid for these drugs is the next topic of

SeYeral laws have been enacted with the sole aim of
pricing procedures on the market.
Sherman Antitrust Act of 1890 is the principal act that
Others include the Clayton Act
price discrimination, tying contracts,
and etc.; the Federal Trade Commission Act
established to enforce the provisions of

le Clayton Act; and the Robinson-Patman Act of 1935 which
Prohibits the granting of different prices to different
commodities of like grade and quality, where the
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effect of such practice is a reduction in competition .
Generally, United States wholesalers ' and manufacturers'
prices are not controlled.

At retail level however, some

eentrol exists, particularly, through cost control in the
atate medicaid programs.1 8

In some European countries, a

product cannot be registered if the price is unreasonable.
france and Italy have formally frozen prices on pharma•eutical products.

Others have ordered a price roll-back.

Economic considerations play a major role in the
registration of drug products in many Europena countries.

for example, in several of the E.uropean countries, a product
cannot be registered if the price is unreasonable.

This is

•xpected to be a major consideration in the United States
when the National Health Insurance becomes a reality.
In Ni geria, the consideration for registration of drugs
s basically safety.

Economic considerations are of low

riority except when the government initiates competitive
idding for drug sales among drug companies.
The Price Control Board has not been very effective in
dealing with rising prices of commodities in Nigeria.19
!he government has, however, taken reactionary steps during
xtreme price hikes by the various industries, particularly,
he food industry .

Roll-backs are recommended where prices

are found to be unjustifiably high.

So far in the pharma-

ceutical i ndustry, no price controls have been ordered and

it .

is highly unlikely that there will be significant controls

n the Pharmac eutical industry at some future time.
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In Ni geria, as in many other places, the pricing of drugs
is affected by the method of buying, which does in turn,
suggest resale values .

The process commonly used by the

Nigerian Army, which is a major drug purchaser, is a competitive bidding system called "tender".

Using its monopsony

power, the government can and does set price limits on drug
products in t he Nigerian drug market .
~ender

Drugs obtained through

are given duty-free certificates and their resale prices

are often muc h cheaper, comparatively.20
Some multinational companies have taken advantage of
lack of adequate price control regulations in the developing
countries whe re prices of many drugs have increased by more
than 100 perc ent in the last few years. 21
The me t hod of transfer-pricing adopted by some multinational drug c ompanies is another problem which developing
nations such as Nigeria have to contend with.

In Colombia,

South America, certain tranquilizers were sold at 4,000
to 4500 perc ent higher than alternative world market prices.
In Iran in 1960s , intermediate bulk chemicals sold at between

38 and 1000 percent higher than in developed nations where
the bulk chemicals were manufactured.

The price of the

intermediate chemical would obviously have an effect on the
ice of dosage forms.
Distribution and Restrictive Sale
The method of distribution and the control on drug
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products depend mainly on what type of drug is under consieration.

Three classes of drugs will be discusseds

Oyer-the-counter (OTC) Drugs

-

These are drugs that are made available directly to the

;urchaser without prescription.

Controls imposed on such

drUgs are similar to those imposed on the distribution of
commodities under the provisions of the Uniform Commercial

Code (UCC).

The potential danger posed by this class of drugs

has been minimiz ed by the "?-point label" required on all
G!C drugs in the United States.

The ?-point label is as

followss
1.

the name of the product.

2.

the name and address of the manufacturer, packer,
or distributor.

J.

the net contents of the package.

4.

the established name of all active ingredients and
quality of other ingredients whether active or not.

5.

the name of any habit-forming drug contained in the
preparation.

6.

the cautions and warnings needed for the protection
of the user.

?.

adequate direction for safe and effective use.22

OTC drugs are available through many outlets where commodities

are sold.
etc.

They are available at supermarkets, pharmacies and

However, some OTC products are made ava1·1 a bl e to the

Ublic exclusively through pharmacies.

are also known as OTC ethicals".
'the Public. 23

This group of drugs

They are not promoted to
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The distribution of OTC drugs in Nigeria is through various
nvenient outlets such as supermarkets, patent medicine stores,
,.und-trucks and, of course, pharmacies.

Patent medicine

stores and sound trucks are similar ±n their practice except
trucks are mobile forms of patent stores.

The

sound trucks usually go from one place to the other selling
drugs.

The patent medicine stores, according to Egboh,24

have out-numbered pharmacies more than ten-fold; and they are
engaged in selling all kinds of drugs including those which
are available only under a doctor's prescription.
There are no regulations controlling the sale of OTC
drugs in Nigeria.

No provision is made in the Nigerian Food

f!ld Drug Decree for thecontrol of the distribution of any

If' these drugs, and for that matter, there is no provision
W.de about this class of drugs in any of the Nigerian laws.

It is assumed, however, that manufacturers, particularly,
foreign manufacturers, will conform to the requirements of
~he regulation ~ of their home countries to control the sale of

over-the-counter drugs.
lrescription Drugs
The distribution of prescription drugs is carried out
pharmacies and physician ·offices.
out, they are being sold

But as Mr. Egboh

over-the-counter by Nigerian

Pl.tent medicine stores.25
The 1951 Durham/Humphrey Ammendment to the Food, Drug and

2!smet·ic Act categorizes the kinds of drugs that may be dis-
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pensed

by

the pharmacist only on the prescription "of a

practitioner licensed by law to administer such drugs".

iuch drugs must bear the legend - "Cautions
hibits dispens ing without prescription.

11

All

Federal Law pro-

Hence the term,

•legend drug" in reference to this class of drugs.
Other requirements of this ammendment are as followsa
1.

It prohibits refilling of such prescription without
expressed authorization of the prescribing physician.

2.

It provides for oral or telephone prescriptions of
legend drugs.

3.

It provides for oral or telephone authorization of
refills of legend drug prescriptions.26

In Nigeria, through the provisions of the Dangerous Drug

6!l, the pharmacist, physician, dentist, and the veterinarian
the authority to handle prescription drugs which are
Q;al.led "poisons" and classified into six parts:
I.

Crude dangerous drugs such as raw opium, coca leaves
and Indian Hemp (Marijuana).

II.
III.

Prepared opium.
Medicinal Dangerous Drugs (with the exception of
Cocaine and marijuana, all drugs listed in this
part are derivatives of opium).

IV.
V.

External Trade in dangerous drugs.
Trade in new Drugs.

VI. General.
ordered on items in Parts I and II is as followsa
(a)

No one other than a registered pharmacist shall
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sell poisons included in parts I and II.27
On part III , it says that these drugs can only be obtained (a)

On signe d order by qualified persons,

(b)

on prescription by those who are qualified by this
Act (doctors, dentists and veterinarians).

On part IV (trade in new drugs), it says as followss
(a)

or

person shall sell or import poisons included
in part IV unless he or she is a registered
pharmacist,
~o

(b) a person holding a license to import part IV
poisons. 28

Parts V and VI are in essence a repetition of the regulations
ln parts I and IV.
It is not known how these classifications are arrived
at.

But, with them are a list of do's and don'ts which in

the final analysis are saying exactly what the United States
Durham/Humphrey ammendment is saying, viz:

that certain

drugs cannot be dispensed to the public by

the pharmacist

unless by prescription written by qualified individuals who
have been certified to do so.
What these regulations prohibit, in brief, is the sale
Of dangerous drugs such as morphine, heroin and marijuana
(particularly those drugs which the United States would
classify as schedule ' II drugs), unless they are on prescription
written and signed by authorized individuals.

Obviously,

118.rijuana and heroin are out of place in this list.

It is

certainly not the intention of the Nigerian legislators to
elude marijuana in the category of drugs which can be
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lspensed by the pharmacist on prescription only.*

The

effects of the Durham/humphrey ammendments on the States is
two-fold.

Apart from reducing the incidence of illicit

traffic in drugs, particularly those with abuse and misuse
otential, it sets limits on the distribution of these drugs
through legitimate channels by limiting the number of allowable prescription refills and requiring more extensive recordieeping. 29
The Pharmacy Practice Act is not as clear in its focus
as the Durham/Humphrey Ammendment.

Its effects on the phar-

maceutical industry is not quite apparent.

However, it can

e concluded from discussions in Chapter IV, that this law
is not being adequately observed.
Controlled Drugs
As indicated earlier, legal restrictions on the distribution of a drug depends to a large extent, on the characteristics of the drug in question.

Controlled Substances are

perhaps the most restricted commodities in any country, whether
lgeria or the United States.
There have been massive efforts to control Narcotics and
ther dangerous drugs through treaties, protocols and interftational convent ions.

The emphasis has been on the restriction

t the production of opium to medical and scientific needs.

•the Provisions of the Indian Hemp Decree supports this
contention.
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he United States has participated in all conventions, treaties
and protocols since 1909.

Nigeria participated in the convention of 1961 (Single
Convention on Narcotic Drugs) for the first time as an independent nation.JO

At this convetion it was decided that

nations which at that time "permitted quasi-medical use of
opium ... and coca leaves", shall take, within a period of

25 years (beginning from 1961), steps to eliminate such practices.31
Three Acts stand prominent in Nigeria, that deal with
the manufacture, sale and distribution of narcotic drugs.
These are as follows:
1.

The Dangerous Drug Act

2.

The Controlled Substances Act and

J.

The Food and Drug Decree.

!he Poison and Pharmacy Act provides guidelines for the pharmacists in the process of carrying out his duties within the
boundaries of the law.
Dru

Acts

DDA

This Act lists some 100 drugs which are subject to restrictions in the areas of importation, exportation, sale and
iatribution.
ortation and Ex ortation
Import Certificate or the Export Authorization must be
Obtained from the Comptroller of Customs before such import

and Distribution
Since the sale and distribution of drugs are mostly
effected by the pharmacist, the control of such is under
guidelines set by the Poisons and Pharmacy Act.

Under its

provisions, a pharmacist musts
1.

Ensure that a precription for controlled drugs
is genuine.

2.

Not dispense the drug more than once unless it
is so specified by the prescribing physician.

J.

Make a record of the sale and keep such a record
for at least two years.

Among other restrictions imposed on the physicians as regards
the prescription of controlled drugs, he (the physician)
shall not be authorized to prescribe a medicinal dangerous
drug for his or her own use". 32
But for this restriction on the physician, there is a
striking similarity between the provisions of the Nigerian
erous Dru
use

Act and the United States Comprehensive Drug

Prevention and Control Act of 1970.

While some states

Jl'Ohibit such practice, the general rule in the U.S. is that

a physician may

wri~e prescription for schedule II drug for

ia personal use provided he is doing so "in good faith 0 .33
The ~ covers drugs such ass

morphine and its deri-

meperidine and related substances and methadone and
•lated compounds.

By the United States classification, most

ot these drugs belong to Schedule II.
e Controlled Substance Act of 1 68
This decree was

CSA

enacted in 1968 to deal specifically,

66.
with the importation, sale and distribution of amphetamine
and amphetamine-containing products.

However, it was repealed

by the enactment of the Food and Drug Decree of 1974.
Drug Decree of 1974
-Food and
The Fo od and Drug Decree
in Nigeria.

(FDD) replaces many of the drug

Controlled Substances are dealt with under

provision of paragraph J of the decree which says1
Except as authorized by the regulation, no person
shall i mport into Nigeria or export therefrom,
manufacture, sell, distribute or cause to be distribute d (whether as samples or otherwise) any of
the drugs specified in schedule II of this decree.34
Schedule II drugs are those which are classified under schedule
Controlled Substances Act of the United States.
Part A of Schedule II of the decree consists of the

DET, DMHP, DMT, ISD, Psilocybin, STP, DOM and TetrahydroIt also includes the Amphetamines and derivatives,
drugs, and all preparations containing some
of amphetamine. '
But for the inclusion of the amphetamines 'Jm this _section
list could have been referred to as an extract of the
nited States schedule I drugs, with some minor addition.
Part B of the devree deals with the following class of
gss

1.

Sedat ives and hypnotics - barbiturates

2.

Non-barbiturate sedatives and hypnotics - glutethimide methyprylon, etc.

J. Skeletal Muscle Relaxants - Meprobamate

4.

Tranquilizers e.g. the phenothiazines

5.

Central Nervous System Stimulants - Caffeine

6.

Adrenergics e.g. Ephedrine and its salts

7.

Artificial Sweeteners such as Cyclamtes*

!he list includes other drugs such as cobalt preparations,
metallic tin and its compounds, potent antibiotics such as
chloramphenicol and its preparations and many others.
The controls on these drugs are similar to the controls
imposed on drugs listed under the Poisons and Pharmacy Act.
The classification seen above consists of drugs that
can be classified under Schedule I through V of the United
States CSA depending upon the potential for misuse and abuse
of the particular drug in question.

Many of the drugs listed

on the other hand, are not subject to the control of the
eontrolled Substances Act of the United States, for example,
cyclamates have been banned in the United States; Ephedrine
and

its salts are not under the provisions of the CSA, and

l'affeine is widely sold over-the-counter.
In most of the drug laws, there appears to be an overlap

n the restrictions imposed on importation, exportation,
Manufacture, distribution and etc. of all kinds of drugs with
the exception of OTC drugs which apparently are not subject
to any kinds of restrictions.

More confusing is the attempt

to classify the controlled drugs and separate them from non-

-See App en d.ix for complete list
.
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controlled, legend drugs.

For . example, the idea behind the

splitting of Part A and Part B of schedule II of the FDD into
two groups and subjecting these t wo groups into identical
legal restric tions is not clearly understood.

It is known

that Part A is a list of highly abused drugs which are grouped
into schedul e I of the United States CSA.

To subject this

group of drugs to the same standards required of drugs in
Part B is i nappropriate.
It can be seen that there are only minor differences
between the CSA of the United States and the provisions of
the Nigerian FDD and the other two Acts in the control of
the distribution of narcotics in both countries.

It appears

that the Nigerian law is, in part, an extract from the United
States law with only minor additions which, when taken together
litake the Ni gerian law on controlled drugs rather more conservative and more stringent.
Mr. J. Pink* has said that the "escalation of drug
legislation by a "leap-frogging motion" probably arises from
countries see ing protections enjoyed by other countries (and)
clamouring fo r even better protection in their own (countries)
without recognizing the debit effects that go with them. 35
11

The "debit effects" in this case can be hypothesizeda
1.

It i s not certain that Nigeria has adequate resources
(manpower and financial capital) to monitor and
establish an effective control of the industry with

an adviser to Wellcome Foundation Ltd. (U.K.)
matters affecting the pharmaceutical industry.

the result that some of the laws passed are never
enforced.
2.

Some of the laws are not appropriate to the prevailing conditions in Nigeria, particularly in cases
such as the restrictions imposed on distribution of
caffeine and the adrenergics which in many cases are
sold over-the-counter in the United States.

3.

There is less incidence of drug abuse and misuse
in Nigeria than there is in the United States and
such controls are unnecessary.

Promotion and Advertising
With the exception of the law that specifies that detail
aen have to be qualified in pharmacy, not legislations have
been passed to control the promotion of drugs in Nigeria.
However, the advertisement of drugs is controlled through the
provisions of paragraph 3 of the Food and Drug Decree.

It

s~ysa

Save as otherwise provided, no person shall:
(a) advertise to the general public any food, cosmetic, or device as a treatment, preventative
or cure for any of the diseases, disorders, or
abnormal physical states specified in schedule
I to this decree. OR
(b) sell any food, drug ..• that is represented on
the label or is advertised to the general public
as a treatment .•. for any of diseases •.. specified in schedule I.*
The blanket prohibition on the advertisement of drugs

Used in the treatment of the diseases . listed in schedule I
*See APPendix ..4, for complete list of diseases in schedule I.
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is rather broad.

It implies, for example, that drugs used

in the treatment of common colds can be advertised provided

they do not contain antihistaminics, which incidentally, are
also used in the treatment of hay fever.
w~ich

Neo-synephrineCR),

may be used in combination with other drugs for the

treatment of bronchial asthma, cannot by implication, be
advertised.

Rheumatic Arthritis is another ailment listed in

aehedule I.

Obviously, it is not the intention of the legis-

lature to prohib it the advertisement of aspirin and aspirincentaining drugs which are widely used in the treatment of
r~eumatic

arthritis.

The inclusion of gastrointestinal

111.cers in the list may also be questioned since there is a
wide application of antacids in the management of this disease.
lany of the drugs in the categories mentioned are widely sold
~er-the-counter

in Nigeria.

Alternatively, it is not clear why many diseases are
from the list.

Malaria, emphysema, bronchitis,

diseas es and many others are not listed.

It is

"Plied that drugs used in the management of these diseases
flan be advertised.

There are certainly many loopholes in this particular
'Plrt of the Food and Drug Decree which make it very difficult
understand and difficult to enforce.

The effect of this

the manufacturers can be theorized.
The Nigerian law against misbranding is analogous to the
ited States law of 1906 which prohibits adulteration and
Paragraph 5 of the FDD states that:
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No person shall:label, package, treat, process, sell or advertise
any food, drug, cosmetic or device in a manner
that is false or is likely to create a wrong
impression as to its quality, character, value,
composition merit or safety.
It is apparent from the typical drug advertisement seen in
the course of the research that manufacturers may be circumventing the provisions of this law by failing to give
proper direct ions for the use of the drugs just as they did
after the enactment of the Federal Pure Food and Drug Law of

1906.)6

Roche's advertisement of Valium(R) in the United

States and in Nigeria is a typical example of the activities
of the drug companies.

In the Nigerian advertisement, Roche

promotes only all the attributes of the drug and merely refers
readers to the packing slip for more information.

In the

United States the same company not only wrote out information
concerning the attributes of the drug, but also included the
contraindications, warnings, precautions, dosage, management
Of overdose and how the drug is supplied.

All these are

required by the United States FDA and the FTC.

Moreover,

the advertising contains reference to Roche's complete product information guide for more information.
Another example is the Merck, Sharp and Dohme's advertisement of Aldomet (R) in both countries.

In the United States

»aper, there is practically complete prescribing information;
but in Nigeria, the information made available is sparse and
incomplete.
Even in the United Kingdom, which in most instances,
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serve as a model for marketing activities in Nigeria, the
United Nations Conference on Trade and Development reported
thats
" •.• recent investigations •.. showed that several
TNCs (Transnational drug companies) were selling
several hunrlred drugs which had been withdrawn
from the American market by the Food and Drug administration as "lacking evidence of effectiveness." 37
An example of this is seen in the case of an American drug
company which makes a brand of chloramphenicola
The manufacturer has had difficulties with the
United States authorities for years over the undesirable side effects of the drug and has paid over
a million dollars in damages for failing to warn
of these effects. Yet it continues to promote
this drug heavily in the United States and other
countries; in the U.S., however, it is required
to warn against six conditions in which the drug
should not be used, in the Federal Republic of
Germany and Australia only one, and in several
developing countries, none at a11.38
Industries in Nigeria have enjoyed major concessions
from the government in form of incentives such as tax relief,
low tariff rates for imported products, etc.

But recently,

several changes have been made and are being made which
threaten those incentives in some cases or eliminate them
completely in others.

The pharmaceutical industry is not very

threatened at this time, but their incentives have been drastically reduced.
The marketing of drugs is controlled by several government agencies in the United States, on the contrary such a
responsibil ity is charged to one agency in Nigeria called
the Food and Drug Advisory Council ctreated only in 1974.
The Nigerian pharmaceutical law, particularly as
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by the provisions of the Food and Drug Decree,
etreates an illusion that there is adequate control over the
activities of the drug industry when in fact, it is full of
loopholes that provide incentives for unscrupulous marketing
practices.
Although there is no evidence of widespread illegal
practice by the drug companies in Nigeria, conditions are
condusive for such practice, particularly when competition
becomes more vigorous.

Such evidence has been found in other

developing countries where drug laws are as relaxed as they
are in Nigeria.

Prices have been found to be excessively

high in countries of South America where conditions are similar
Nigeria's.
In many cases, Nigeria's drug laws are subject to various
interpretations depending on

individual~s

interests and in

instances, the laws are ahead of the United States drug
in level of stringency.
It has been found that Nigerian drug laws in some instaare analogous to the United States laws in the late 1930s
conditions were similar to the conditions in Nigeria at

The Food and Drug Decree's classification of drugs into
Schedules is one of the most confusing aspects of the law.
It has different unrelated criteria for each group of drugs
or medical supplies.

In this case, the United States laws

much clearer and more logical in sequence.
In general, however, the laws in both countries are
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similar in context, and the same trend in escalation of
pharmaceutical laws by a "leap-frogging motion" in other
countries, particularly in the United States, is currently
in motion in Nigeria and catching up to the United States is
a matter of time.
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VI.

SURVEY OF PHARMACEUTICAL COMPANIES

It was recognized that because this survey dealt primarily
with sensitive areas of pharmaceutical business practice, there
might be a problem in securing response from people in the
industry.
Consequently, care was taken to design the questionnaire
in such a way that respondents would not feel threatened, nor
would they provide self-serving answers.

Thus, the questions

were designed to ensure that responses could be obtained
from the participants without sacrificing any vital information in the process.
Appendix 4 presents a copy of the questionnaire used in
this study.

The first seven questions were designed to pro-

vide a profile for the responding companies in both countries,
particularly in determining the type of personnel in charge
Of their Nigerian operation, and also in determining their

Bales volume in both countries for three consecutive fiscal
Jears.

It was also designed to enable readers to know the

current status of individual company's level of operation in
areas of manufacturing.

For companies which do not currently

engage in manufacturing (and they are presumed to be many),
reasons for such action were asked.
The questions were also designed to determine what
companies produce what products and what individual companies'
leading products are on the Nigerian market.
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The next four questions (#8 through 11), were included
in order to determine how much concern the companies have
tor product registration in Nigeria.

They were also designed

to understand how much emphasis they place on the testing
of products prior to marketing in order to compare their
responses with that portion of the Nigerian law which deals
with this issue.

Responses to these questions would provide

an insight into the pharmaceutical companies' operations in
Nigeria vis-a-vis the government regulations.
The succeeding six questions were included in order to
measure the comparability between number of attempts by the
pharmaceutical industry to introduce new drug products in
both countries to the number of approvals in both countries.
Responses received would provide information on the preference
of the manufac turers in introducing new drugs.

When the

number of attempts are compared to the nuniber of approvals,
it will be possible to determine the relative difficulty in
getting products approved based on the knowledge of the laws
in both countries.
A knowledge of the number of United

States Food and

Drug Administration unapproved drugs currently sold in Nigeria

by the industry would provide answers to the desirability of
introducting products in Nigeria where the pharmaceutical laws
are more relaxed.

It will also provide answers to possible

enticing marketing opportunity that prevails under such
relaxed conditions.
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The rest of the questions are designed to determine how
the Unite d States fares with regard to trade concessions which
at the moment only the United Kingdom enjoys.
Answers to a question on how the registration and drug
introduc tion laws of both countries are comparable with each
other would certainly provide a confirmation concerning what
has been empirically known for a while.
Out of the sixty-five questionnaires mailed - fifty-two
in the United States and thirteen in Nigeria - only six were
returned fully or partially filled out for a response rate of
approximately nine percent.
Fourteen respondents wrote back refusing to participate
in the s tudy for various reasons.

Some of them referred all

questions about their operations in Nigeria to their European
headquarters.

However, these headquarters never responded

either.
Some of the letters written by the non-participants
included information that indirectly answers some of the
questions raised in the questionnaire.

For example, some

companies have reduced their operations in Nigeria and have
resorted to merely exporting to that country as a result of
the government policy of having forty percent participation
in all fo reign investments in Nigeria.

Others indicated that

their ope rations in Nigeria are in the preliminary stages
and therefore they could not contribute anything of major
Bi.cn-.·r·
0 " 1 icance to the study.

Some companies stated flatly

that the y do not make such information public as a matter
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of corporate policy.
From the six responses obtained, profiles of individual
respondents will be made and where responses are incompletely
supplied, i nformation about the particular company will be
tilled in, ba s ed on further research .

A synopsis of the

eompanies' responses to these questions will be made with
latent awareness of the limitations imposed by low response
rate.
The foll owing sections present results by questions (see
Appendix J for a copy of the survey instrument used).
Company Profile
?

One of the responding companies is a subsidiary of a
large corporation with diversified operations.

Its operation

is international in scope and has sales in the billion dollar
range world-wide .

It lists its world-wide sales of $400

million in Medical Supplies for this company for fiscal year

1975.

It reports that it is against company policy to report

Bales by i ndividual countries.

It does not have a manufacturing

facility i n Nigeria because of the Nigerian government regulations and the country's political instability.

It lists

its major products in Nigeria as vitamins and prenatal
Vitamin supplements.

It is also involved in marketing of

antibiotics to a lesser proportion.
Another respondent is a relatively small cmpany with
Projecte d pharmaceutical sales of $190 million in the United
States for the current fiscal year.

It lists projected sales
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of $1 million in Nigeria for the same period.

The respondent

for this company is the Area Director for Nigeria, himself
based in the United States headquarters.

It too does not

engage in any manufacturing in Nigeria.

It indicates that

Nigerian policy of participation in foreign investments in
Nigeria is particularly responsible for its action.

It is

involved in the sales of antidiarrheals (its number one
product in

Nigeria), oral contraceptives, neuroleptics, anti-

spasmodics and antinauseants - all in order of decreasing
importance.
The third company is one based in the Southeastern United
States.

The person in charge of Nigeria is the Director of

Operations for Middle East and Africa.

It is a company which

specializes in Cough and Cold Medicines in both countries
under consideration.

It lists other products sold in Nigeria

as muscle relaxants, gastrintestinal analgesics, antidiarrheals
and digestives.

It does not report sales both in the United

States and in Nigeria.

'

However, sales in the United States

are in the hundreds of millions of dollars.

This company

does not manufacture pharmaceuticals in Nigeria because "sales
(in Nigeria) are nat large enough to support a factory."
The fourth company is a relatively small one based in
North-Eastern United States.

Sales volume reported shows

a consistent decline over a three year period.

It has its

headquarters in Europe and it indicates that its operations
in Nigeria are controlled through the European head office.
The headquarters never responded to requests for information.
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Its products are exported to Nigeria and it deals primarily
in local anesthetics in the Nigerian market.

The fi fth respondent is the Public Relations Officer for
the entire company.

He represents a large company based in

the North Eastern United States.

He states that sales are

not broken down by product class - a system very unusual in
the pharmaceutical industry.

It also indicated that its sales

in the various overseas countries are not made public.

It is

a company with a relatively large operation in Nigeria.
It does not manufacture its products in Nigeria because,
says the Public Relations Director, "the market is currently
adequately s upplied."

Its major products in Nigeria are

antibiotics, appetite stimulants, anthelmintics, antihypertensives and lastly, antiarrythmics.
The sixth and the last company which responded has its
headquar ters in New York City.
Nigerian market.
in Lagos, Nigeria.

It is highly involved in the

It has a $4 million factory opened recently
It is highly specialized in the production

and sale of antibiotics.

It is also involved in other areas

Buch as in anthelminthics, antiseptics, vitamins and antidiarrheals - in that order.

The responding person is the

Divisional Manager who is based in Lagos, Nigeria.

His was

the only response received out of the thirteen questionnaires
Jllailed to Nigeria.

He too did not make available his company's

Bales fi gures from the Nigerian market.
The r esponses received were from pharmaceutical companies

With Wide variety of therapeutic class of drugs.

All the
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responding companies are international in scope.
engage in exportation of drugs to

Nigeria.

has a manufacturing facility in Nigeria.

Most of them

Only one of them

Only one of them

listed sale s volume in the United States over the three
periods r equested for.

One other listed sales in both countries.

Five of the six companies do not manufacture pharmaceuticals in Nigeria, some for economic reasons and some for political and legal reasons.
GOVERNMENTAL RESTRAINT ON MARKETING
Approval of Drugs before Marketing
The Nigerian Government through the provisions of the
Food and Drug Decree of 1974 requires that all companies
obtain governmental certification before marketing.

Four of

the five companies responding to this section of the questionnaire ind icated that their companies do get approval from the
Nigerian Government before marketing their products.

One

indicate d that it does not have to obtain such an approval,
a practic e which is inconsistent with Nigerian law.
reasons may be attributed to this practice&

Three

(1) The company's

responding officer is the Public Relations Director who may
not know what the situation is like in Nigeria, but has to
respond to the questionnaire perhaps because of pressure from
superior officers in the company; (2) The company is deviating
from normal practice because of an apparent lack of adequate
enforcement of this portion of the pharmaceutical law;

(3) The company is taking advantage of the law which specifies
that drugs approved for sale in the country of manufacture
may be sold in Nigeria but not before obtaining a license to
to so.

Careful analysis of the company's answers to the re-

maining questions, however, supports the conclusion that the
latter t wo of thethree reasons enumerated above best explain
the company ' s actions .
Company's Liaison Officer with the Government
In t he United States , most drug companies, it is presumed,
have public relations and government relations officers who
serve as l iaison between the company and the government.
This by i tself emphasized the importance of rapport between
companies and the government.

It is even more important in

areas where approval of drug products for marketing are desired.
One of the companies indicated that the distributing

firm in Nigeria acts as the liaison between the company and
the government.

Two companies indicated that they do not

have an officer on their staff and two others indicated that
they do.
It can be suggested that:

(1) These companies, parti-

cularly those who do not have such officers on their staff
simply cannot afford the "luxury" of keeping such a staff
on their payroll in Nigeria; (2) Some other company personnel
in the company is responsible for such activities and therefore
it will be a waste of employees• time and the company's money.
However , it all boils down to one thing:

that product
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registration in Nigeria to those companies may not be of
major concern.
,tests Required on Products Before Marketing in Nigeria
The Nigerian Food and Drug Decree requires only the
proof of safety before a drug can be approved for marketing.
However, the United States through the provisions of the
Food, Drug and Cosmetics Act requires the proof of safety
as well as efficacy before a product can be approved for
marketing in the United States.
The safety requirement is embodied in the series of
pre-marketing testing which all potential new drugs go
through in the United States.

This question is asked as

follo ws:
(a)--- -toxicology
(b)-- --clinical
(c)---- efficacy
(d)-- --safety
(e)----s tability
(f)----o ther
This question was asked in order to find out if the
Pharmaceutical companies do conform to the requirements as
specified in the Food and Drug Decree.

It is designed to

determine the standard of quality demanded of the drug
industry as understood by them.

As demonstrated in Chapter

IV., the Food and Drug Decree consists of many loopholes that
give room for unethical practice by some in the industry who
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may desire to do so.
General agreement on the types of tests required of
respondent would be a positive indication that they, at
least, understand the law, and in all probability they would
abide by it.
One of the responding companies indicated on the questionnaire that clinical, efficacy, stability and other tests
besides toxicology and safety are performed.

Possible tests

that may fall under the "other" category couldbe any or all
of the following:

terratogenic, bioavailability, pharmaco-

kinetics, etc.
The Nigerian based respondent listed the followings
toxicology, efficacy, safety, stability and other tests
except clinical which he indicated is performed "sometimes".
Other companies either did not respond or indicated on the
questionnaire that data were not available.

One of the

respondents indicated that no tests were required as long
as "clinical support is available from elsewhere."
It can be seen from the first case above that "safety"
and "toxicology" are not indicated as any of the tests

required on potential drug products in Nigeria.

The latter

company (the only response from Nigeria), indicated that all
tests except "clinical" (which is performed "sometimes"),
are performed on its products before marketing.
It can be seen from these responses that there is no
general agreement among the participating companies on the
kinds of tests which have to be performed on potential
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new products in Nigeria.

In contrast, as demonstrated in

Chapter IV, these tests are embodied in a battery of clinical
and animal testing as required by the provisions of the
Investigational New Drug (IND) and the New Drug Application
(NDA) in the United States.
From these responses, these is evidence to suggest a
general lack of understanding of the various drug laws of
Nigeria among the respondents, particularly, those laws that
deal with drug manufacturing.

Such a lack of understanding

might be explained as follows&
1.

Nigerian laws do not clearly delineate tests that
have to be performed on potential new drugs and
therefore such decisions are dependent on the industry's ethical values.

2.

Nigeria's health delivery system cannot afford the
"luxury" of such tests and some of the drug companies
recognize this and therefore perform such tests as
they deem fit.

Rate of Drug Approval in Both Countries
Companies were asked about the approval rates of drugs
in both countries in order to determine if conditions are
such that international drug companies would be encouraged
to introduc e drug products in Nigeria before doing so in the
United States.
Out of the three which responded to the questions, one
indicated that out of four applications submitted in the
Period between 1974 and 1976, three were approved and two

of the approved drugs are actually on the market.

Another

one stated that out of four submitted, all four were approved
for marketing and all four were actually on the market.

The

Nigerian- based responding company stated that nine applications were submitted and all nine were approved for marketing
in Nigeria.

Six of these products are currently being sold

in Nigeria.
An even more limited response rate was received regarding
United States approval.

One company stated five applications

were submitted to the Food and Drug Administration during
this period, only one of them which is currently on the
market was approved for marketing.
None of those who responded to the first set of questions
about approval rate in Nigeria also responded to the latter
three about the United States approval rate.
difficult to make the comparison desired.

This makes it

The lack of res-

ponse to either one set of questions or the other is not likely
to be a happenstance - except in the case of the Nigerian
respondent which believed that the answers to the second
set of questions could only be supplied by the headquarters.
The approval rate in Nigeria is better than 90 percent
for the three companies which supplied this information.
Over the three year-period, a total of seventeen applications
Were made, sixteen of these were approved, and a total of
twelve products out of the sixteen approved are currently
on the market.

This is a success rate of approximately 70

Percent between the development of new drug products and the
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actual marketing in Nigeria.
As seen from Chapter V, Table 4 of this study, the number
of new drugs introduced into the United States market has
declined from 400 in 1957 to 87 in 1968.

Seventy percent

of all new discoveries never make it beyond the laboratories.
This study has found that high approval rates were achieved
in Nigeria.

However, limited evidence obtained for the

companies' United States operations are simply inconclusive.
United States Unapproved Drugs in Nigeria
Questions 18, 19 and 20 of the questionnaire are designed
to deal with the marketing of FDA-unapproved drugs in foreign
countries, particularly Nigeria.

One of the respondents

indicated that out of the four or five such drugs in foreign
markets, three are in Nigeria.

None of the three was comple-

tely developed in the United States.
done in the United States."

"Some work on each was

Another one of the respondents

stated that "specific data (on unapproved drugs) were not
available (but the number of such drugs) was believed to be
few."

None of them, it indicated, is on the Nigerian market,

and none was developed in the United States.

One other

company indicated that no United States unapproved drug is
in any forei gn market.
!._cceptability of United States-Supplied Data
Two of the responding companies indicated that data
obtained from and analyzed in the United States are satis-
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factory to the Nigerian officials "most of the time".
The responses of these companies suggest that information
provided on specific drugs in the United States are readily
accepted by the Nigerian officials.

However, limitations

imposed by low response rate makes it very difficult to be
conclusive.
Comparison Between the Two Systems
This is the only question responded to by all the participants and there is a general agreement that new drug
introduct ion legislation is more difficult in the United
States than in Nigeria.

VII.

CONCLUSION

General Differences
The United States, when compared to Nigeria, has approximately three times the population , thirteen times the
physical size, fifty times the Gross National Product and is
several t imes greater in technical and scientific advancement.
The United States is approximately 200 years older than Nigeria,
but both gained -their independence from the United Kingdom.
Nigeria's present general level of development is comparable
to the United States in the 1930s, particularly in areas of
pharmaceutical laws.
Life expectancy in Nigeria is estimated to be about 40
years compared to about 72 in the United States.

Nigerians

are afflicted with preventable diseases such as malaria,
tetanus, meningitis, diarrhea, cholera, and so on while the
United States is afflicted with physiological dysfunctions
and disorders reflective of their life expectancy.
Twenty-nine of the

50 states in the United States surpass

Nigeria in the number of pharmacists, while 27 states have a
greate r number of physicians, and all
dentis ts .

50 states have more

The United States surpasses Nigeria in per capita

figures in all categories of health professions.
M_edical and Pharmaceutical Practice
The Nigerian native doctors play a powerful role in health
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care de livery.

But the people are becoming more sophisticated

in the ir health care demands and are seeking care from less
primitive sources (physicians, dentists, pharmacists, etc.),
where a scientific approach is more prevalent.
There is considerably less distinction between the practice of the Nigerian physicians and pharmacists and their
counterparts in the United States; but relations between these
two groups are just as subtle.

Although there are clear

distinctions in the statutory limits on the practice of either
profess ion, there is some overlap in their practice as seen
in this study.

It has been suggested in this study that

there may be flaws in the enforcement mechanism of the laws
enacte d to guide the practices of these professionals.
Evolution of Pharmaceutical Laws and Practice
Although pharmaceutical laws and practice evolved in
both countries in different time frames, the general development took place in similar forms.

In both countries, the

Pharmacy profession was subjected to intimidation; in Nigeria
by the national government until 1969, and in the United
States by the medical profession at much earlier times.
The laws have developed through evolutionary means in
the United States, but in Nigeria, the pace has been in fact,
almos t r evolutionary at certain points in history.

Laws have

been enac ted in the United States mostly as a result of
traumatic national episodes (e.g. elixir sulfanilamide) or
international experiences (e.g. thalidomide).

On the contrary,
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in Nigeria laws have been enacted mostly as a result of major
trends in pharmaceutical laws of the United Kingdom or the
United States.
Government Controls
The controls imposed on the pharmaceutical industry's
activit ies the world over are escalating in a "leap-frogging"
motion.

The escalation is greatest in the United States

where most of the world production and consumption of drugs
are carried out.
Although drug consumption levels in Nigeria are insignificant when compared to the United States, the same trend in
escalat ion of drug laws is shaping up gradually.

However,

the drug laws enacted are full of many loopholes which could
make the enforcement of these laws very difficult.
They also contain many confusing sections that make the
laws difficult to understand.

Says SCRIP in its comments

about section 1(1)(c) and section 4(b) of the Food and Drug
Decree that "while one may not sell an article of food which
consists wholly or in part (inter alia) of "filthy, disgusting,
rotten or diseased substance", it would appear that the only
restric tion for cosmetics are filth, decomposition and foreign
matter.

A cosmetic which contains a "disgusting" substance

seems to be OK. "
Similar comments can be made regarding safety requirements imposed by the Food and Drug Decree.

It appears that

as long as the premises in which drugs are manufactured are
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clean, the safety of the drugs is guaranteed.
I n the United States, the control of the production and
distribution of drugs is charged to several government
agencie s; but in Nigeria only one agency of the government
is responsible.
Although there is no evidence of widespread illegal
practic es by the pharmaceutical industry, conditions such as
unenforc ed price laws, lack of adequate controls on advertising
materials , inadequate controls on manufacturing of drugs, are
conducive to such practices.

These conditions are similar

to those existing in some of the developing nations of South
America where evidence of illegal and unethical practices
have be en seen.
ATTITUDES OF PARTICIPANTS
The six respondents represent only a small section of the
pharmaceutical industry in Nigeria.

Most of the respondents

and indeed many of the companies operating in Nigeria are
only engaged in the preliminary stages of potentially large
marketing operations and therefore appear to be reluctant
to supply needed data for fear of giving out trade secrets.
Many of the respondents do not have manufacturing facilities and operate only by importing products from overseas
countries - using the services of distributors.

Generally,

the re sponding companies have a reserved feeling about
making large capital investments in Nigeria because of the
Political climate and also because of the incessant search
by the government for regulatory forces on the Nigerian
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industrial front.

Others see a hope in the Nigerian market

particularly because of

the recent surge in business, but

will wait and watch until the time is ripe when conditions
become sufficiently promising to warrant a local capital
investment.
There are wide insonsistencies between the drug laws of
Nigeria as seen in previous chapters adn the responses of the
participating companies.

These inconsistencies suggest that

there is general lack of understanding of parts of the Food
and Drug Decree of 19?4.
From the responses obtained, it appears that new drug
introduc tion in Nigeria is of no major concern to the drug
companies.

Overall approval rate in the United States for

the thre e periods requested is approximately eight percent
for the entire industry compared to a rate of more than 90
percent for the companies which responded.
At least two of the responding companies indicated that
they are marketing some United States FDA unapproved drugs
in forei gn markets.

One of the two indicated that it has

three such products on the Nigerian market.

All the

respondents agreed that new drug introduction legislation
is much easier in Nigeria

than in the United States.

Although there is a significant difference in the approval rates of drugs in the United States and Nigeria, the
number of companies that participated in the study has made
it difficult to make any conclusive report.

However, it can

be suggested that approval rates in Nigeria appear to be
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higher.

In addition, all respondents perceive drug intro-

duction legislation to be less stringent in Nigeria.

RECOlVIMENDATIONS FOR FURTHER STUDIES
This study has been hampered by a low response rate to
the que stionnaires.

But its value cannot be underestimated

for the reason that it opens up several areas that can be

investigated upon much further and at a broader scale.
Further studies can be embarked upon as case studies on
selected c ompanies that enjoy the confidence of the investigator.

Appendix 1
LETTER OF INTRODUCTION

~

UNIVERSITY OF RHODE ISLAND

99 ,

KINGSTON, R. I. 02881
College of Pharmacy • Department of Pharmacy Administration • 401-792-2735

oear Mr.
All f acets of the health care industry, particularly the
pharmaceutical industry, are constantly reminded of the controls
imposed by government.
In order to measure the impact of some of these statutory and
regulatory provisions on drug product marketing in the domestic
and foreign markets, a study is being conducted by the University
of Rhode Is l and Department of Pharmacy Administration.
Since the principal investigator for whom this study is a
thesis proj ect is a Nigerian national, the comparisons are between
the United States and Nigeria. It is particularly signifieant that
this resear ch is being conducted during the implementation phase
of the Th ird National Development Plan of Nigeria.
Your c ooperation and response will help to make this a meaningful and useful study, the report of which might provide insight
into and foc us upon the nature of the existing conditions in the
two countri es under consideration.
Pleas e be assured that every measure will be taken to assure
confiden t i ality of responses. Names are solely for tabulation purposes and participants will not be identified · in the thesis.
Loo~ ing forward to receiving the stamped, self-addressed rereturn ~ve•lope containing your completed questionnaire very soon.

Shoul d you have any question, please do not hesitate to write

~ call e ither signer of this letter.

Thank you.
Sincerely

~~~~.
fessor and Chairman

Enclosures

Sincerely,

· 1l-~~'L.- MJ~AILL'~f r
Ph.D.

Tunde Adenodi, B.S.
Graduate Teaching Assistant

Appendix 2

REMINDER LETTER

UNIVERSITY OF RHODE ISLAND
KINGSTON, R. I. 02881
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College of Pharmacy • Department of Pharmacy Administration • 401-792-2735

January 21, 1977

Dear Mr.
re:

Questionnaire about U.S. & Nigerian Drug Laws

We are reminding you about the questionnaire that was mailed
to you on December 28, 1976.
Since the analysis of responses to the questions raised is essential to the conclusion of the study, it is important that we receive the completed questionnaire.
If you have any doubts about any of the questions raised,
please comment on such questions and procede to the others. It
will serve to enlighten us on the validity of such questions.
We will be looking forward for your response.
Sincerely,

a. ~

Norman A. Campbell, J.D. ,Ph.D.
Professor aud Chairman

Tunde Adenodi
Graduate Teaching Assistant

Appendix J
QUESTIONNAIRE
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1. Name of company~----------------------~------------~
2. Name of respondent (optional)

J. Total domestic sales (Pharmaceuticals):
A) Current fiscal year (projected)

Current fiscal year -1
C) Current fiscal year -2
B)

$
$
$

4. Total Nigerian sales (Pharmaceuticals), if applicable:
A) Current fiscal year (projected) $
B) Current fiscal year -1
$

C) Current fiscal year -2

$

5. Does your company manufacture pharmaceuticals in Nigeria?
Yes

No

6. If answer to question #5 is "No", why is your company not
manufacturing in Nigeria?
A)
no marketing potential
B)
government regulations
C)
political instability
D)
not a company objective
E)
reason unknown

7. What are the five leading therapeutic classes of drugs sold
in Nigeria by your company? (Please list in rank order,
the highest assigned a value of 1, and the least, a value
of 5.)

3.

4.

-----------------~----------~----

5 · ----~----------8. Does your company have to obtain Nigerian government approval
before marketing its products in Nigeria? ___Yes ___No

9. Does your company have a governmental liaison officer
responsible for product registration in Nigeria?
__Yes ___ No
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1. Name of company---~~---~-------~~~------~~
2 . Name of respondent (optional)

J. Total domestic sales (Pharmaceuticals):
A) Current fiscal year (projected) $------~B) Current fiscal year -1
$________

C) Current fiscal year -2

$_______

4. Total Nigerian sales (Pharmaceuticals), if applicable:
A) Current fiscal year (projected)
B) Current fiscal year -1

C) Current fiscal year -2

$
$
$

5. Does your company manufacture pharmaceuticals in Nigeria?
Yes

No

6. If answer to question #5 is "No", why is your company not
manufacturing in Nigeria?
A)
no marketing potential
B)
government regulations
C)
political instability
D)
not a company objective
E)
reason unknown

?. What are the five leading therapeutic classes of drugs sold
in Nigeria by your company? (Please list in rank order,
the highest assigned a value of 1, and the least, a value
of 5.)
1•

3.
4.

5.

------------------

-------------------------~------

------------------

8. Does your company have to obtain Nigerian government approval
before marketing its products in Nigeria? ___Yes ___ No

9. Does your company have a governmental liaison officer
responsible for product registration in Nigeria?
__Yes __ No
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10. Are you required to conduct any tests on your products
in Ni geria before distribution? ~Yes ~No
11. If "yes" what tests are required?
A)
B)

C)
D)
E)
F)

toxicology
clinical
efficacy
safety
stability
other

12. How many new products did you submit applications for the
Nigerian government between 1974 and 1976?_ _ _ _ _ __
13. How many of these products were approved for marketing in
Nigeria?
14. How many of these products are actually on the market?
15. How many NDA's did your company submit to the US(FDA) Food
and Drug Administration between 1974-1976?_ _ _ _ _ __
16. How many of the products were approved for marketing?
17. How many of them are on the U.S. markets? ______________
18. How many U.S. unapproved drugs are on any foreign market?
19. Are any of the U.S. unapproved drugs on the Nigerian
market?------20. How many of the U.S. unapproved drug products were
developed in the U.S.?_ _ _ _ _ __
21. Are data on imported drugs obtained from and analyzed in

the U.S. satisfactory to the Ni gerian officials?

A)

all the time
B)
most of the time
C)
sometimes
_
_
_
_
never
D
22. How would you compare new drug* introduction and re gistration laws of both Nigeria and the United States?
A) ___more difficult in the U.S.

105

B} _ _more difficult in Nigeria
C)_~no difference
23. Please check the statement below if you desire to get
a copy of the result of investigation.
I wish to receive a copy of the result of the investigation.

*New drugs are drugs which are new on the Nigerian market or
new development for Nigerian patients.
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SCHEDULES
Section 2

SCHEDULE I
DISEASES, ETC. REFERRED TO IN SECTIO:>i

2

Alcoholism
Appendicitis
Arteriosclerosis
!Asthma
'-BTood disorders

~-·

~;;

'"·

·::.;,

C~ncer

\.

Cataract
Diabetes
Cholera
Diphtheria
Disorders of menstrual flow
Disorders of prostate gland
Dysentery
Encephalilitis
Enteric fever
Epilepsy
Erysipelas
Filariasis
Gallstones, kidney stone,;, and bladde r stones
Gangrene
Any genital or urinary di seases not mentioned eise,·.-here in this Schedule
Glaucoma
. ._ Goitre
FeYer
Heart disease
Hernia
High blood pressure
Infective hepatitis
Influenza
Jaundice
Kidney disease
Leprosy
Locomotor ataxis
Loss of youth
Measles

Q1ay

Meningiti~

Mental conditions
l\.111mps
Nervousness
Nutritiona l disorders

I,/

\

...
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·'
-----------------------------

SCHEI>ULE 1- coutinued
( >hc,;ity
( )nchocl'rciasis
Paralysis
Plague

._

Pleurisy
l'11e11 rnon ia

~

., .

Poliornyditis

Rahi(·s
Hheunrntic fcn·r
Schistoso111iasis
Sexual impotrncc, bss of \·irility or sterility
Slt:cpin~ sickness
Smallpox

{

1',•

··~

\.

\

-~

~·
...,,_.
. -'.

Snake hitc

Syphilis
Tl'tanus

Trad10111a
T11ben.:11losis
T11n1011rs
Typhoid fcn-r
Undulant fcn~ r
Vlccrs of the gastro-intl'stinal tra..:t
\'cncrl'al <liseas..:s
Yaws

Yellow frn:r.
Scclio11 3
D1wc;~

HEFE1rnw To I:--i SECT IOi\

....

3

Part.·/

DET
D!\1 Ill'

(N, :'\-dietliyltryptamine)
(3-( 1,2-dirnet hylhcptyl)- 1-hy<lrox: -7, 8, 9,
1() tct r:ihnlro-(i, 6, 1J-trimcthvJ-(, H -dibcnzo
(h,9) pyr.an)
·

Di\IT

(N, :'\-dimethyltrypta111inc)
(- I·)-:'\, :\"-diet hyllyscrgami<lc ( J-lysc;·gic
acid dil'thylamidl')
(3, .f.. :'i -trimcthoxyphrncthyla111 i11c)

LYSEHGlllE/1.!>D , l.SJ>-25

:\lcscalinc
paralil·xyl

·")

(3-lil'\_\'l-1-h:dro.\y-7 , ~. 9, lfl-lc\1altydn1'l-triml'tliyJ-(,11-dibcnzo (h,J) pyran)

(1, (1 ,

psiloci nc, p~ilotsin
P~Il.OC\"Uli\E

( .\-( 2-dimcth _1· la111i11oct h yl)-+-h yd rnxy i11
dole)

(3-(2-di1nl'thyLnni1111l'thvl) imlol-.f.-yl dihydn•gl'n ph os l'h ;1 lt')

' ·'

...,_.,.,.,.,....._ __,,_..,..,................,-~_,.,~_,,....,_,.....~...-....--..,,..
... .......,..,.......

~---,...--_..,,c..,.,......,,~,

. 44>

~,. ... ca

>

P

z . "9~""':....,,_..,.
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- -- - .

109.
Food and Dru;s

STP,

DOl\I

tctrahy<lrucannahin•ib,
all isomers

(Z-amino-1-(2. 5-Jimctho:.;y-4-mcthyl)
phcnyl-prnpan<')
1-hydruxy-3-p..:ntyl-fo, 7. 111. l!la-tctrahy<lro-6, 6, 9-trimcthy!-6-Il-dibt:nzu (b,<l)
pyran

( + )-2-ami111>-l-phcnylprupJnc)

Dl:."XAl\IPltET,\!\llNE

i\J F.TI IAi\I PllET:\;\I l :\E

\
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(+)-2-amino- l-pitcnylpropmc)
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(+)-2-mcthylamino- l-p~cnylp1opane
(2-phcnyl-2-(2-pipcridyl) act:tic aciJ,
methyl est<'r)
( 3-mcthyl-2-phen y I mor? holi n..:)
{l-(1-phenykylohC':xyl) pi pet it.line

i\hrrtlYl.PJIE!':IDATE
PHENi\IETRA7.l:\E
!'HF.NCYCLIDl:\E

Any synthetic C'ompoun<l or salt (however :.truLtural!y dcriveJ) uf
Amphetamine or of any substance of the like nature ~ .-\m?hctar.1;nc.

Part B
(5-ethyl-5-(3-meth::lhu y!) barhit11ric aciJ)
(5-( l-cyclohcxen- l-yl)-5-cthylbarbituric
acid)
(2-cthyl-2-methybmino- l-pht:n yi-prop-

Al\IOBARBJTAI.
CYCl.OIJARilJT,\L
GLUTETllll\llDE ••

ane)
(5-cthyl-5-( 1-methylbut~·! )
(5-allyl-5-(1 mcthylhu:.\ l) bar!:iituric acid)

PENTOBARllITAL ••
8ECOB.>\RU!TAI.

{2-( d iethylami ne) p r<J p!r,}-the1, :mnc
(5, S-dicthy!b :1rbit u~ ic a:::d)

Al\lfEl'R:\i\IO:SE
J!AROITAL

cthchlorvynol
ETJIINA:\!ATE
i\frrttOll:\;\!:\TE

. .

l\J F.TllAQL'Al.O:-<E
:\ JETI I YI .PllE:\011 .\H flt TA!.
MF.TllYPRYt.O;-.; ••

l'HENOBAHUI L \I.
P1rnAnno1.

SrA
CouAt:r

C'thyl-2-chlorO\·inyll.. h: :1 ~· ~-c.:rbi 11ul
1- ct hyny lcyduhcx;, nu~ c.1.-bd111at l'
2-mcthyl-2-propyl-l, : -p rnpJtH:Jiul :lic.irbamate
2-mcthyl-3-u-tolyl-+ (.; HJ- quinazolinonc
5-cthyl-l-mcthyl-5-phc:n:: l-harbitut ic aci<l
3, 3-<liethyl-5-mcthy!-2. +-pipc:idi0n 1: 5-ethyl-5-phcnyl barbi: 1: iic a-: id
1, 1-diphcnyl- l - I -(2-p ipeiidyl) mC't hanol
(-)-1-dimcthybm irn:- l. 2-<liphrnyl<.:tha:i..:

l'HEl'.\HATto:-is

CY<.:l.IZINE
SuLrttAi\IETI 1oxYnt .\Z t:S-E

Su1.1•11,\n1 ~1ET1 1ox 1~ E

A:-.llNOPYIU1\ E

:\;\!)

Dtl'YRUNE

An:cAH11no;\1 ,\I .
CARllHO;\l.\l.

llno:-.HSOVAI.

l\I1:.1·At.t.1c 'f1:--; A:-11> ir:; Co~11·ot.l'\1J~
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Part B - co11ti1111f rl
fatPTEN (2-(P-hminophcnyl)-cthylglyt:irimi<le)
l\·JF.Cl.OZINE

DmuoNor. 2. 2-thiubis (4, 6-dichlorophenol)
hl!PR.'\MINE
EFOCAJNE
.

XF.NAzo1c

·~<I:.

..:~

~·.'\

KF.ONOV1 :.\I

Aero on XENAI.A:\IINE
IonmE

' ("I.

DITHLAZ:\l'\I::-iE

~ '1

=~;.,

CJILORPIIENTF.!UllNE
CYCLA'.\J:\TES, CYCLOHEXYl.BJl::-;E A="<D THEIR DF.RIV:\TI\".ES
COMPHF.TA!\tlNES
CHLOR.\:\ll'!IENICOL .'L'ID ITS PREPAll.\TIO);S
CAFFEINE •.,...
EPHEDRIN ANO !TS. SALT

3

SCHEDlJLE

Section S

PUDLir.ATIO:-;s REFEHRED TO IN SECTION

5

Pharmacopoeia Internationali:;
Any other pharmacopoeia published under the authority of a recognised
medical or pharmac<:utical cou ncil of :iny country .

/

.

SCIIED"CLE

Dnucs n EFrnnrn To 1:-.;

4

SEcno:-.;

Sfclion i

7 (1)

Liver extract in ::ill forms
Insulin in ::ill form~
Anterior pituitary extracts
Radioacti\·e i::otopcs

....

Living vaccines for oral or parentcr:il use

I

Drug;; prepared from micro-organisms or virusc~. for parenteral u.;e
Sera and drugs analng"llS thereto, for parenteral use
Antibiotics for parenteral use.
~

,

SCHEDULE

Ont.res HEFEH llED

To IX

Ar~phennmine

Dichlorophcnar~inc hydrochloride
Ncoarsphcnamine
Oxophenarsli irw hydrochloride
Sensitivity di~cs :ind tablets
Su lpharspl1cn;iminc

5

SF.cTJoN 7 (2)

Section 7·

~-
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